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Abstract
ANALYSIS AND IMPLEMENTATION OF A POSITIVITY PRESERV-
ING NUMERICAL METHOD FOR AN HIV MODEL
Jo-Anne Wyngaardt
MSc Thesis, Department of Mathematics and Applied Mathematics, University of
the Western Cape.
This thesis deals with analysis and implementation of a positivity preserving nu-
merical method for a vaccination model for the transmission dynamics of two HIV-
subtypes in a given community. The continuous model is analyzed for stability and
equilibria. The qualitative information thus obtained is used while designing numeri-
cal method(s). Three numerical methods, namely, Implicit Finite Difference Method
(IFDM), Non-standard Finite Difference Method (NSFDM) and the Runge-Kutta
method of order four (RK4), are designed and implemented. Extensive numerical
simulation are carried out to justify theoretical outcomes.
Keywords: HIV model(s), stability, reproduction number, equilibria, Implicit fi-
nite difference method, Non-standard finite difference method, Runge-Kutta method,
preservation of positivity, analysis of the numerical methods.
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Chapter 1
Introduction
This thesis deals with the analysis and implementation of a positivity preserving
numerical method for a typical HIV model. The main goals achieved in this thesis
are necessary descriptions of some theoretical and numerical tools to handle such a
model for HIV. These techniques can be used/extended in an analogous way for other
modified models (as can be seen shortly in forthcoming sections) where other factors
are incorporated which may eventually lead to some more complex terms and/or
equations in the system. In order for one to be able to understand the relevence of
the problem, we introduce below what is known as HIV.
1.1 What is HIV?
HIV is an acronym for the phrase “Human Immunodeficiency virus”. This virus
causes AIDS (Acquired Immuno-deficiency Syndrome). The people infected with HIV
are eventually killed through AIDS. Infections by the virus HIV-1 (one of the most
common type of HIV for which there exist several subtypes as described in section
1.4) has many highly complex characteristics, most of which are still not understood
[62]. The fact that the disease progression can last more than 10 years from the first
day of infection is just one of them. Another is that while most viral infections can
1
 
 
 
 
be eliminated by an immune response, HIV can be controlled only partly by it.
HIV primarily infects a class of white blood cells or lymphocytes, called CD4
T-cells. The virus has a high affinity for a receptor present on the cell surface of
each of these cells which guides the virus to their location in vivo. When the CD4
T-cell count, normally around 1000/µL, decreases to 200/µL or below, a patient is
characterized as having AIDS.
One would think that these CD4 T-cells can fight against the HIV virus. Unfor-
tunately, these cells are the hosts for the HIV virus once a person is infected. The
HIV virus turns these cells into virus producing factories, making many copies of the
virus. The virus then weakens the immune system and may even kill more of these
CD4 T-cells. Because of the central role of the CD4 T-cells in immune regulation,
their depletion has widespread deleterious effects of the functioning of the immune
system as a whole and this is what leads to AIDS.
1.2 HIV vs AIDS
The first reports of AIDS was in April 1981, when five men appeared in different
hospitals around the Los Angeles district [29]. They were all very ill with unusual
symptoms. The most common factor about these five patients, was that they were
all homosexual. It was then thought that the disease only affected homosexual men
and heroin addicts. During the early days of AIDS the disease was called GRID
(Gay-Related Immune Deficiency). Before the end of 1981, similar cases were found
in non-homosexual groups. Some drug users aquired it via bloodstream. When they
found that the disease can infect both men and women, the name GRID was no longer
appropriate and it changed to AIDS (Acquired Immuno-deficiency Syndrome).
Acquired indicates that the unknown causative agent is transmitted to human be-
ings exogenously, from external sources in the course of their natural life span, rather
2
 
 
 
 
than passed endogenously, in the germ line.
Immune-deficiency indicates that symptoms result from a fault in the immune
system (the very bodily mechanism that has evolved to combat disease).
Syndrome indicates that there are a range of symptoms associated with the in-
fection, rather than a single disease.
During the early days of AIDS, there was a mystery around it. People were asking
many questions like, what is AIDS, where does it come from, why is this happening
now, how does it spread, etc. AIDS was also considered forbidden territory. People
did not talk openly about it, as we do today. It was then thought that HIV causes
AIDS.
Virologists Luc Montagnier, Jay Levy, Robert Gallo and their teams [41] isolated
the same retrovirus, but only Montagnier and Levy had correctly diagnosed the virus.
According to them, the virus is not an oncovirus (a virus associated with cancer) as
Gallo thought, but is a lentivirus, because of its slow pathogenic course within the
body (Note that the lentivirus is a genus of slow viruses of the Retroviridae family,
characterized by a long incubation period. It can deliver a significant amount of
genetic information into the DNA of the host cell). Gallo and Montagnier struggled
for several years about primacy. In March 1987 Ronald Reagan (the then President
of USA) and Jacques Chirac (French Prime minister) called a press conference to
announce the renaming of this retrovirus which is known today as Human Immuno-
deficiency Virus (HIV).
Nowadays, we hear a lot about HIV from the media. Many educational and
medical institutions started educating people publically about AIDS and HIV. More-
over, effective antiretrovirol drugs (ARVs) are being developed to treat HIV infected
individuals.
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1.3 History and status of HIV in South Africa
South Africa is currently experiencing one of the most severe HIV epidemics in the
world. By the end of 2005, there were five and a half million people living with HIV in
South Africa [6], and almost 1000 AIDS deaths occurring every day around the globe,
according to UNAIDS estimates [77]. A survey published in 2004 found that South
Africans spent more time at funerals than they did having their hair cut, shopping
or having barbecues. It also found that more than twice as many people had been to
a funeral in the past month than to a wedding [73].
South Africa has had a turbulent past, and this history is relevant to the explosive
spread of HIV in the country. Below we describe (chronologically) the different stages
and measures taken regarding this epidemic in South Africa [6] which indicates that
how the disease was evolving despite the various initiatives taken by the government:
1980s: In 1985, a State of Emergency was declared in South Africa that would
last for five years. This was a result of riots and unrest that had arose in response to
Apartheid (the system of racial segregation that had been in place since the 1950s).
Apartheid prohibited mixed-race marriages and sex between different ethnic groups,
and categorised separate areas in which different races lived. In the same year, the
government set up the country’s first AIDS advisory group in response to the increas-
ingly apparent presence of HIV amongst South Africans. The first recorded case of
AIDS in South Africa was diagnosed in 1982, and although initially HIV infections
seemed mainly to be occurring amongst gay men, by 1985 it was clear that other
sectors of society were also affected. Towards the end of the decade, as the abolition
of Apartheid began, an increasing amount of attention was paid to the AIDS crisis.
1990: The first national antenatal survey to test for HIV found that 0.8% of pregnant
women were HIV-positive [81]. It was estimated that there were between 74,000 and
120,000 people in South Africa living with HIV. Antenatal surveys have subsequently
4
 
 
 
 
been carried out annually.
1991: The number of diagnosed heterosexually transmitted HIV infections equalled
the number transmitted through sex between men. Since this point, heterosexually
acquired infections have dominated the epidemic. Several AIDS information, training
and counselling centres were established during the year.
1992: The government’s first significant response to AIDS came when Nelson Man-
dela addressed the newly formed National AIDS Convention of South Africa (NA-
COSA). The purpose of NACOSA was to begin developing a national strategy to
cope with AIDS. The free National AIDS helpline was founded.
1993: The National Health Department reported that the number of recorded HIV
infections had increased by 60% in the previous two years and the number was ex-
pected to double in 1993. The HIV prevalence rate among pregnant women was 4.3%.
1994: The Minister for Health accepted the basis of the NACOSA strategy as the
foundation of the government’s AIDS plan. There was criticism that the plan, however
well intended, was poorly thought and disorganised. The South African organisation
Soul City was formed, with the aim of developing media productions to educate peo-
ple about health issues, including HIV/AIDS.
1995: The International Conference for people living with HIV and AIDS was held
in South Africa. The then Deputy President Thabo Mbeki, acknowledged the seri-
ousness of the epidemic, and the South African Ministry of Health announced that
around 850,000 people (2.1% of the then total population) were suspected to be HIV-
positive [66].
5
 
 
 
 
1996: The HIV prevalence rate among pregnant women was 12.2%.
1997: The HIV prevalence rate among pregnant women was 17.0%. A national
review of South Africa’s AIDS response to the epidemic found that there was a lack
of political leadership.
1998: The pressure group Treatment Action Campaign (TAC) was founded, to cam-
paign for the rights of people living with HIV, and to demand access to HIV treatment
in South Africa for all those who were in need of it.
1999: The HIV prevalence rate among pregnant women was 22.4%.
2000: The Department of Health outlined a five-year plan to combat AIDS, HIV
and STIs [22]. A National AIDS Council was set up to oversee these developments.
At the International AIDS Conference in Durban, the new South African President
Thabo Mbeki made a speech in which he mentioned that the main cause of AIDS is
the problem of poverty and not the HIV. President Mbeki then consulted a number
of dissident scientists who rejected the link between HIV and AIDS.
2001: The HIV prevalence rate among pregnant women was 24.8%.
2002: The honourable High Court of South Africa ordered the government to make
the drug ‘Nevirapine’ available to pregnant women to help prevent mother to child
transmission of HIV. Despite international drug companies offering free or cheap an-
tiretroviral drugs, [71] the Health Ministry remained hesitant about providing treat-
ment for people living with HIV.
2003: The government approved a plan to make antiretroviral treatment publicly
6
 
 
 
 
available. The HIV prevalence rate among pregnant women by the end of this year
was 27.9%.
2004: The South African government’s treatment program began to take effect in
Gauteng (one of the nine provinces in South Africa), followed by other provinces.
2005: At least one service point for AIDS related care and treatment had been
established in all of the 53 districts in the country, meeting the government’s 2003
target. However, it was clear that the number of people receiving antiretroviral drugs
was well behind initial targets. The HIV prevalence rate among pregnant women was
30.2%.
2006: A senior politician was taken to trial for allegedly raping an HIV-positive
woman. He argued that she had consented to sex and was eventually found not
guilty, but attracted controversy when he stated that he had showered after sex in
the belief that this would reduce his chances of getting infected with HIV. Criticism
of the government’s response to AIDS heightened, with UN special envoy Stephen
Lewis attacking the government as ‘obtuse and negligent’ at the International AIDS
Conference in Toronto. At the end of the year, the government announced a draft
framework to tackle AIDS and pledged to improve antiretroviral drug access. Civil
society groups claimed that this marked a turning point in the government’s response.
Further upcoming informations regarding various issues associated with HIV and
AIDS can be found in [6].
1.3.1 The South African Department of Health Study, 2005
Based on its sample of more than 16,510 women attending antenatal clinics across all
nine provinces, the South African Department of Health Study estimates that 30.2%
of pregnant women were living with HIV in 2005. The provinces that recorded the
7
 
 
 
 
highest HIV rates were KwaZulu-Natal, Mpumalanga and Gauteng.
Until 1998 South Africa had one of the fastest expanding epidemics in the world,
but HIV prevalence is now growing more slowly. Among teenage girls, the rate de-
clined from 1998 to 2002, and has since risen only slightly, indicating that the rate
of new infections may have peaked. Historical prevalence figures can be found in our
South Africa as indicated in the Tables 1.1 and 1.2.
Because infection rates vary between different groups of people, the findings from
antenatal clinics cannot be applied directly to men, newborn babies and children.
However, some simple calculations can yield an approximate estimate of the total
number of people living with HIV in South Africa.
Based on the antenatal data, the study estimates that 6.29 million South Africans
were living with HIV at the end of 2004, including 3.3 million women and 104,863
babies. In producing these data, it is assumed that pregnant women accurately
represented all women aged 15 - 49 years, that men are 85% as likely to be infected
as women, and that 30% of babies born to infected mothers will themselves have HIV
(ignoring any reductions due to preventive action).
1.3.2 The South African National HIV Survey, 2005
The National HIV Survey is a “household” survey. This involves sampling a pro-
portional cross-section of society, including a large number of people from each ge-
ographical, racial and other social groups. The researchers took great pains to try
to make the sample as generalized as possible, and the findings are later adjusted
to correct for likely over- or under-representation of individual groups (according to
census data).
The surveyers visited 12,581 households across South Africa, of which 10,584
(84%) took part in the survey. Of the 24,236 people within these households who
were eligible to take part, 23,275 (96%) agreed to be interviewed and 15,851 (65%)
agreed to take an HIV test. This means that only 55% of eligible people were tested.
8
 
 
 
 
Table 1.1: Province-wise estimated HIV prevalence percentage among antenatal clinic
attendees [6]
Province 2000 2001 2002 2003 2004 2005
KwaZulu-Natal 36.2 33.5 36.5 37.5 40.7 39.1
Mpumalanga 29.7 29.2 28.6 32.6 30.8 34.8
Gauteng 29.4 29.8 31.6 29.6 33.1 32.4
North West 22.9 25.2 26.2 29.9 26.7 31.8
Free State 27.9 30.1 28.8 30.1 29.5 30.3
Eastern Cape 20.2 21.7 23.6 27.1 28.0 29.5
Limpopo 13.2 14.5 15.6 17.5 19.3 21.5
Northern Cape 11.2 15.9 15.1 16.7 17.6 18.5
Western Cape 8.7 8.6 12.4 13.1 15.4 15.7
National 24.5 24.8 26.5 27.9 29.5 30.2
Table 1.2: Age-wise estimated HIV prevalence percentage among antenatal clinic attendees
[6]
Age group (yrs) 2000 2001 2002 2003 2004 2005
<20 16.1 15.4 14.8 15.8 16.1 15.9
20-24 29.1 28.4 29.1 30.3 30.8 30.6
25-29 30.6 31.4 34.5 35.4 38.5 39.5
30-34 23.3 25.6 29.5 30.9 34.4 36.4
35-39 15.8 19.3 19.8 23.4 24.5 28.0
40+ 11.0 9.8 17.2 15.8 17.5 19.8
The main reasons given for refusing HIV testing were fear of having a blood
sample taken (58%); religious objections to having a blood sample taken (16%) and
not wanting to learn HIV status (7%). A further 13% of people who refused were,
for various reasons, afraid or mistrustful of the survey. The report of the survey
claims that people at high risk for HIV infection were more likely to take part, and
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the results were adjusted to compensate for this perceived bias. The response rate is
considered “good” by the standards of this type of survey, but is considerably lower
than that found in other parts of sub-Saharan Africa [70].
Based on this survey, the researchers estimated that 10.8% of the South Africans
over previous two years were living with HIV in 2005.
1.4 HIV types, groups and subtypes
HIV is a highly variable virus which mutates very readily. This means there are many
different strains of HIV, even within the body of a single infected person. Based on
genetic similarities, the numerous virus strains may be classified [6] into types, groups
and subtypes.
There are two types of HIV: HIV-1 and HIV-2. Both types are transmitted either
by sexual contacts or through blood, and also from mother to child. These subtypes
appear to cause clinically indistinguishable AIDS. However, it seems that HIV-2 is not
easily transmitted, and the period between initial infection and illness is longer in this
case. This type of HIV is concentrated in West Africa and is rarely found elsewhere.
Therefore, the predominant virus (worldwide) is HIV-1, and generally when people
refer to HIV without specifying the type of virus they mean it as HIV-1.
As is mentioned in Figure 1.1 (page 11), the strains of HIV-1 can be classified
into three Groups : the “major” Group M, the “outlier” Group O and the “new”
Group N. These three groups may represent three separate introductions of simian
immunodeficiency virus into humans.
While more than 90% of HIV-1 infections belong to HIV-1 Group M, Group O
appears to be restricted only to the West-Central Africa whereas the Group N -
discovered in Cameroon (in 1998) - is extremely rare.
Within Group M there are known to be at least nine genetically distinct subtypes
(or classes) of HIV-1, namely, subtypes A, B, C, D, F, G, H, J and K.
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HIV − 1 HIV − 2
B C D F G H J K CRFsA
Group M Group N  Group O
Figure 1.1: Classification of HIV into Various Groups
Occasionally, two viruses of different subtypes can meet in the cell of an infected
person and mix together their genetic material to create a new hybrid virus (a process
similar to sexual reproduction, and sometimes called “viral sex”) [16]. Many of these
new strains do not survive for long, but those that infect more than one person are
known as “circulating recombinant forms” or CRFs. For example, the CRF A/B is a
mixture of subtypes A and B.
The classification of HIV strains into subtypes and CRFs is a complex issue and
the definitions are subject to change as new discoveries are made. Some scientists
talk about subtypes A1, A2, A3, F1 and F2 instead of A and F, though others regard
the former as sub-subtypes. One of the CRFs is called A/E because it is thought
to have resulted from hybridization between subtype A and some other “parent”
subtype E. However, no one has ever found a pure form of subtype E. Confusingly,
many people still refer to the CRF A/E as “subtype E” (in fact it is most correctly
called CRF01 AE).
A virus isolated in Cyprus was originally placed in a new subtype I, before being
reclassified as a recombinant form A/G/I. It is now thought that this virus represents
an even more complex CRF comprised of subtypes A, G, H, K and unclassified regions.
The designation “I” is no longer used [31, 75].
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The HIV-1 subtypes and CRFs are very oddly distributed throughout the world,
with the most widespread being subtypes B and C. Subtype C is largely predominant
in southern and eastern Africa, India and Nepal. It has caused the world’s worst HIV
epidemics and is responsible for around half of all infections. Historically, subtype B
has been the most common subtype in Europe, the Americas, Japan and Australia.
Although this remains the case, other subtypes are becoming more frequent and now
account for at least 25% of new infections in Europe. Subtype A and CRF A/G
predominate in west and central Africa, with subtype A possibly also causing much
of the Russian epidemic [12]. Subtype D is generally limited to east and central
Africa; A/E is prevalent in south-east Asia, but originated in central Africa; F has
been found in central Africa, south America and eastern Europe; G and A/G have
been observed in western and eastern Africa and central Europe. Subtype H has only
been found in central Africa; J only in central America; and K only in the Democratic
Republic of Congo and Cameroon.
In the section below, we provide some models which are focused mainly on sub-
types of HIV-1 type described as above.
1.5 Some HIV Models
Ever since the pioneer works of Kermack and McKendrick [48] in 1927, many epi-
demics have been modelled and extensive mathematical analysis has been carried
out for them. The development of mathematical models for HIV models and their
analysis received much attention only in the past two-three decades. In this section
we present some of these HIV models (starting from the simplest one and then their
subsequent modifications) as they have evolved and the available methods for their
solutions.
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1.5.1 Model-I (A single subtype circulating in a community
(with a vaccine))
McLean and Blower [58] described a model that reflects the observed epidemiology
of HIV in San Francisco. The population they considered was an imaginary homo-
sexual population. This model basically investigates a single subtype circulating in a
community.
The total population in this model is divided into four classes:
• susceptibles (X),
• vaccinated (V ),
• infectious (Y ), and
• AIDS patients (A).
The size of sexually active community is denoted by N = X + Y + V which means
that they assumed that AIDS patients are not included. (Note in the above that N
denote the size of sexually active community and not the total population).
The biological assumptions and governing equations of the model are
• Individuals recruited into the sexually active community at a constant rate Π.
• They leave the community at a constant rate µ.
• A fraction ρ of new recruits are vaccinated and it takes a fraction ε on them.
• The risk of being infected depends on per partnership infection probability
β, the average number of new partners per unit time c, and fraction of the
community that are infectious Y
N
.
• Some vaccinated individuals loose their vaccine-induced immunity due to a fi-
nite duration of the vaccine’s effects. The vaccinated individual then joins the
susceptible class at a rate wV .
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Taking the above into account, the rate of change in the number of susceptibles is
dX
dt
= (1− ερ)Π− µX −
βcXY
N
+ wV. (1.1)
The rate of change in the number of vaccinated individuals is given by
dV
dt
= ερΠ− µV − wV −
(1− ψ)βcV Y
N
, (1.2)
where ψ is the degree of protection afforded by the vaccine.
The size of the infectious population is given by
dY
dt
=
βc [X + (1− ψ)V ]Y
N
− (µ+ γ)Y (1.3)
and finally the rate of change in the number of AIDS patients is given by
dA
dt
= γY − (µ+ α)A, (1.4)
where α is the average death rate.
We refer the model constituted by above four equations (1.1-1.4) as the Model-I.
1.5.2 Model-II (The transmission model of two HIV subtypes
without vaccination)
To assess vaccine programs for the control of two HIV subtypes, Porco and Blower
[68] developed mathematical models described below.
Firstly they formulated a model of the intrinsic transmission dynamics of two
HIV subtypes in a homosexual community. The individuals that are in the model are
part of the sexually active community. Out of the various subtypes found through
investigations, they considered any two of these and refered to them as subtype-1 and
subtype-2.
The total population in their model is divided into the following five classes:
(i) susceptibles, X,
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(ii) individuals who are infected with subtype-1 but have not developed AIDS, Y1,
(iii) individuals who are infected with subtype-2 but have not developed AIDS, Y2,
(iv) individuals who have developed AIDS, A1,
(v) individuals who have developed AIDS, A2.
Like the previous model, again the total size of the sexually active community is given
by N = X + Y1 + Y2.
After incorporating necessary assumptions, the model that Porco and Blower de-
veloped is given by the following set of equations
dX
dt
= Π− µX − β1cXY1
N
− β2cXY2
N
dY1
dt
= β1cXY1
N
− µY1 − γ1Y1
dY2
dt
= β2cXY2
N
− µY2 − γ2Y2
dA1
dt
= γ1Y1 − (µ+ α)A1
dA2
dt
= γ2Y2 − (µ+ α)A2,


(1.5)
where α is the average death rate.
We refer the above model as the Model-II.
1.5.3 Model-III (The transmission model of two HIV-subtypes
with vaccination)
This model is an extention of Model-II in which the authors (Porco and Blower [68])
included the effects of vaccination with a prophylactic vaccine.
The fraction of the individuals entering the sexually active community and who
enter the vaccinated community is denoted by ρ. Then a fraction of those individuals,
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who have a protective immune response is denoted by e and hence the fraction of
individuals who are effectively vaccinated is ρe.
The model assumes that the individuals that have been effectively vaccinated
are less likely to be infected. The degree of protection against the infection for an
effectively vaccinated individual is between 0 and 1. Where 0 is for no protection and
1 is for complete prevention of infection for those exposed to a given subtype.
Again the total sexually active community is N = X + V + Y1 + Y2.
Noting that V (t) denotes vaccinated susceptible individuals, the model (taking
into account the above specifications where X, Y1 and Y2 has the same meaning as
mentioned in the previous model) is therefore given by the following set of equations,
altogether, referred to as Model-III:
dX
dt
= Π(1− ρe)− µX − β1cXY1
N
− β2cXY2
N
dV
dt
= Πρe− µV − β1c(1−ζ1)V Y1
N
− β2c(1−ζ2)V Y2
N
dY1
dt
= β1cXY1
N
+ β1(1−ζ1)cV Y1
N
− µY1 − γ1Y1
dY2
dt
= β2cXY2
N
+ β2(1−ζ2)cV Y2
N
− µY2 − γ2Y2
dA1
dt
= γ1Y1 − (µ+ α)A1
dA2
dt
= γ2Y2 − (µ+ α)A2,


(1.6)
where ζ1 and ζ2 denote the degree of protection that the vaccine confers against
infection by the two subtypes in the individuals who are effectively vaccinated and α
denotes the average death rate.
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1.5.4 Model-IV (The transmission dynamics of two HIV sub-
types: modification of Model-III)
The model considered by Gumel [37] is a modification of Model-III. He included per
capita rate (τ) of treatment coverage and excluded the individuals who developed
AIDS from subtype-1 and subtype-2 infection. He also included a recovery rate for
individual in subtype-i, denoted by γi, where i = 1, 2. His model consists of the
following equations:
dX
dt
= Π(1− ρ)− µX −
1
N
β1cXY1 −
1
N
β2cXY2, t > t0, X(t0) = X
0, (1.7)
dV
dt
=Πρ− µV −
1
N
(1− ξ1)β1cV Y1 −
1
N
(1− ξ2)β2cV Y2, t > t0, V (t0) = V
0, (1.8)
dY1
dt
=
1
N
β1cXY1 +
1
N
(1− ξ1)β1cV Y1 − (µ+ γ1 + τ)Y1, t > t0, Y1(t0) = Y
0
1 , (1.9)
dY2
dt
=
1
N
β2cXY2 +
1
N
(1−ξ2)β2cV Y2 − (µ+ γ2 + τ)Y2, t > t0, Y2(t0) = Y
0
2 , (1.10)
where N(t) = X(t) + V (t) + Y1(t) + Y2(t) with
(i) X(t): susceptible individuals,
(ii) V (t): vaccinated susceptible individuals,
(iii) Y1(t): individuals infected with an endemic HIV-subtype 1,
(iv) Y2(t): individuals infected with an invading HIV-subtype 2
and the associated parameters are
• Π: annual recruitment rate of individuals into the sexually active community,
• ρ: fraction of susceptible individuals vaccinated,
• µ: rate of stopping sexual activity,
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• c: number of sexual partners,
whereas for i = 1, 2,
• βi: probability of per partnership transmission,
• ξi: vaccine induced immunity against subtype - i,
• τ : per capita rate of treatment coverage,
• γi: recovery rate of subtype - i.
We refer to this model as Model-IV.
Models presented above are some of the popularly studied models. Other models
can be found in the list of references in the articles cited along with these works.
1.6 Literature Survey
In this section, we briefly mentioned few of the methods developed to solve the models
described in previous section. The works presented in this section are in the chrono-
logical order and is not classified based on any specific model due to the fact that
some of the articles deal with more than one model described earlier. We include
both analytical and numerical approaches to solve such models. We apologise if there
are any omitions which might occured due to unavailability of the literature but are
(of course) totally unintentional.
Anderson et al. [3] described some preliminary attempts to formulate simple
mathematical models of the transmission dynamics of HIV infection in homosexual
communities. In conjunction with a survey of the available epidemiological data
on HIV infection and the incidence of AIDS, the models are used to assess how
various processes influence the course of the initial epidemic following the introduction
of the virus. They mentioned that the models of the early stages of viral spread
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provide crude methods for estimating the basic reproductive rate of the virus, given
a knowledge of the incubation period of the disease (AIDS) and the initial doubling
time of the epidemic. To assess the influence of variation in the incubation period
and heterogeneity in sexual activity, they formulated more complex models.
In [11], Blythe and Anderson studied a proportionate mixing one-sex model of
sexual transmission of HIV and described it in which sexual activity (new partners
per unit time) is defined as a continuous variable in a set of integro-partial-differential
equations. They developed a discrete activity-class approximation by matching equi-
librium state and rate variables as closely as possible with the continuous-variable
model and consists only of ordinary differential equations. Activity-class boundaries
are arbitrary, and each class is characterized by a single level of activity. If there
are N classes, the level of activity in N − 1 of them is such that the steady-state
susceptible class sub-population is equal to the population in the equivalent section
of the continuous model. They chose the activity level for the remaining class in
such a way that the condition for endemicity of the infection in the approximation is
equal to that for the equivalent continuous-variable model and this minimizes errors
in the steady-state population. The relationship between the discrete and continuous-
variable models is explored, via numerical and analytical studies, in order to evaluate
the accuracy of the approximation.
Blythe and Anderson [9] derived distributions describing variation in the incu-
bation and infections periods of the HIV from a series of risk or hazard functions.
Four possible forms of the probability density function are considered, namely, expo-
nential, Weibull, Erlang/gamma, and rectangular, and the properties and underlying
risk functions are compared and contrasted. They also analyzed (both theoretically
and numerically) the models of the transmission dynamics of the virus, encapsulating
different assumptions concerning the distributed incubation and infectious periods.
In [10], Blythe et al. considered two different approaches to the encapsulation of
temporal variation in the infectiousness of HIV-infected persons, and variability in
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the incubation period of AIDS, in simple homogeneous mixing models of viral trans-
mission in male homosexual communities are described. The first approach is based
on the division of the infected population into a series of subclasses with differing
levels of infectivity and different durations of occupancy. The second approach is
more mechanistic in character and is based on an attempt to relate changes in viral
abundance within an infected person to the likelihood that the disease AIDS develops.
Variable incubation is induced by variation in the rate of change of viral abundance
in the infected population. They compared the numerical projections of changes in
the incidence of AIDS through time, generated from both types of model, with pro-
jections based on the assumption of constant infectivity throughout the incubation
period of AIDS. Their model formulation also highlights areas in which more detailed
quantitative epidemiological studies are required. Finally they discuss the methods
of parameter estimation.
Kakeshashi [47] studied the spread of HIV/AIDS in Japan which was analyzed
using a mathematical model incorporating pair formations between adults and sex-
ual contacts with commercial sex workers. The parameters involved in the model
were carefully specified as realistically as possible to the actual situation in Japan.
Plausible ranges were assigned to those parameters for which values are not known
precisely. The model was used to simulate the effect of HIV infected commercial sex
workers introduced into a population without HIV. It was shown that the model could
generate different scenarios, an explosive infection or a temporal spread, according to
different settings of the parameters.
Then the condition for occasional introduction of HIV infected commercial sex
workers to be able to cause an explosive spread of HIV infection was analyzed. This
condition was summarized in terms of the critical transmission probability so that we
could easily evaluate the degree of the risk. For some unclear parameters, sensitivity
to the critical transmission probability was calculated. A plausible range of the criti-
cal transmission probability was also calculated using the Latin hypercube sampling
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method where the parameters were distributed on the plausible ranges. According to
the analyses of the model it was concluded that the actual situation of HIV spread
in Japan should lie very near the critical point that determines whether the explosive
HIV spread actually takes place. This study also suggested that effective action taken
immediately could be useful to prevent explosive HIV infection in Japan.
In [57], May and Anderson reviewed data on HIV infections and AIDS disease
among homosexual men, heterosexuals, intravenous (IV) drug abusers and children
born to infected mothers, in both developed and developing countries. They derived
the estimates of the model’s parameters from the epidemiology data, and predictions
are compared with observed trends. They also combine these epidemiological models
with demographic considerations to assess the effects that heterosexually-transmitted
HIV/AIDS may eventually have on rates of population growth, on age profiles and
on associated economic and social indicators, in African and other countries. They
also discussed about the degree to which sexual or other habits must change to bring
the ‘basic reproductive rate’, R0 of HIV infections below unity.
Boily and Anderson [13] developed a simple model of the transmission of HIV-1
by heterosexual contact and from mother to unborn infant to assess the influence of
patterns of mixing between low and high sexual activity classes of the two sexes on the
pattern of spread of the virus and the demographic impact of AIDS. Their numerical
studies of the model behaviour are based, wherever possible, on parameter estimates
derived from epidemiological studies of HIV-1 spread in Africa. Their analyses reveal
that the assumed pattern of mixing, ranging from assortative (like with like) through
random (proportional) to disassortative (like with unlike), has a very major impact on
the predicted spread of the virus and the concomitant demographic impact of AIDS.
They predicted patterns of strong assortative mixing to generate the least spread
and demographic impact, by comparison with proportional or disassortative mixing.
They also conclude via the analyses that the rules governing behaviour changes, once
AIDS-induced mortality changes the structure of the population (i.e. the numbers
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in the low and high sexual activity classes of the two sexes), have a very significant
influence on the course of the epidemic. They compared the predicted patterns with
observed trends in Africa.
John [45] considered a model of the transmission dynamics of HIV-1 appropriate to
urban areas of Africa and discussed its behaviour explored through numerical studies.
The model is a two-sex model with age-dependent demographic and behavioural
parameters. Adults are classified by age, sex, risk group, and epidemiological status.
He explored sex and age patterns of infection as is the potential economic impact of
changes in the sex and age composition of the population.
Genetic variation is the hallmark of infections with lentiviruses in general and
the viruses (HIV-1, HIV-2) in particular. In [63] Nowak reviewed both experimental
evidence for the variability of the previous HIV genome during the course of an
individual infection and mathematical models that outline the potential importance
of antigenic variation as a major factor to drive disease progression. The essential
idea is that the virus evades immune pressure by the continuous production of new
mutants resistant to current immunological attack. This results in the accumulation
of antigenic diversity during the asymptomatic period.
The existence of an antigenic diversity threshold is derived from the asymmetric
interaction between the virus quasi-species and the CD4 T-cell population: CD4
T-cells mount immune responses some of which are directed against specific HIV
variants, but each virus strain can induce depletion of all CD4 T-cells and therefore
impair immune responses regardless of their specificity. Therefore, increasing HIV
diversity enables the virus population to escape from control by the immune system.
In this context the observed genetic variability is responsible for the fact that the
virus establishes a persistent infection without being cleared by the immune response
and induces immunodeficiency disease after a long and variable incubation period.
Gani and Yakowitz [32] considered a random allocation model for the transmission
of HIV by needle sharing among a group of intravenous drug users who are friends
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or relatives (buddy-users). A Markov chain approach is used to track the increase in
infectives in a stable group of such intravenous drug users, some of whom are HIV
positive. The model is modified to allow for the replacement of infectives in the group,
with the group size remaining constant.
Around 1991-92, a number of prophylactic vaccines against HIV have passed
through phase I of the clinical trials, and phase II clinical trials were being planned.
McLean and Blower [58] mentioned that these vaccines are not expected to be perfect
and might fail in a number of different ways. They showed how to equate different as-
pects of imperfection in a prophylactic vaccine in terms of impact upon levels of herd
immunity, and hence upon the vaccine coverage required for eradication. Such com-
parisons reveal that an otherwise perfect vaccine that gives protection which wanes
with a half-life of 10 years is only as good as a vaccine that works in 30% of peo-
ple giving them complete, lifelong protection. Furthermore, they compare predicted
patterns of seroconversion that would be observed in clinical trials and in community-
wide vaccination campaigns for vaccines that confer the same levels of herd immunity
but are imperfect in different ways.
Theory is linked with data to assess the probability of eradicating HIV in San Fran-
cisco through the use of prophylactic vaccines. In [7] Blower and McLean quantified
the necessary vaccine efficacy levels and population coverage levels for eradication.
They assessed the likely impact of risk behaviour changes on vaccination campaigns.
Their results show that it is unlikely that vaccines will be able to eradicate HIV in San
Francisco unless they are combined with considerable reductions in risk behaviour.
Furthermore, if risk behaviour increases as the result of a vaccination campaign, then
vaccination could result in a perverse outcome by increasing the severity of the epi-
demic.
Mollison et al. [61] discussed that the problems of understanding and control-
ling disease has raised a range of challenging mathematical and statistical research
topics, from broad theoretical issues to specific practical ones. They indicated that
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in particular, the interest in acquired immune deficiency syndrome has stimulated
much progress in diverse areas of epidemic modelling, particularly with regard to the
treatment of heterogeneity, both between individuals and in mixing of subgroups of
the population.
At the same time better data and data analysis techniques have become available,
and there have been exciting developments in relevant theory, ranging from random
graphs and spatial stochastic processes to the structural stability of difference and
differential equations. This progress in specific areas is now being matched by interdis-
ciplinary cooperation aimed at elucidating relationships between the widely varying
types of model that have been found useful, to determine their strengths and limita-
tions in relation to basic aims such as understanding, prediction, and evaluation and
implementation of control strategies. Such interdisciplinary work can be expected to
make major contributions to the modelling of a wide range of human, animal and
plant diseases, as well as to general statistical and biomathematical theory.
Garnett and Anderson [33] presented a mathematical model of the transmission
dynamics of HIV-1 in a heterosexual population stratified by age, sex, and sexual
activity (defined by rates of sexual partner acquisition). The model represents an
extension of previous studies with a special focus on patterns of mixing or contact
between sexual activity and different age classes of the two sexes. A range of mixing
patterns between these groups is specified for both sexes. Mixing is described on
two scales from fully assortative to fully disassortative, with random defined either
according to numbers of sexual partnerships or numbers of people.
Above authors mentioned that the sexual partnerships in the model are balanced
by changes in the rates of sexual partner acquisition between particular groups and
a range of changes, from only women changing behaviour to only men changing
behaviour, are analyzed. The pattern of mixing is most influential in determining the
shape and magnitude of the epidemic, but the manner in which people choose partners
(i.e., dependent on numbers or proportions in the population) is also important.
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They also illustrated relative importance of variation in transmission probabilities
and mean rates of partner change on the course of the HIV epidemic. They indicated
furthermore that the analysis of the sensitivity of predictions to changing parameters
in the force of infection term of the model provides a theoretical basis from which the
influence of control strategies and the demographic effects of HIV can be analyzed.
In [35] Greenhalgh and Hay developed and analyzed a model for the spread of
HIV/AIDS amongst a population of injecting drug users. Their work is based on a
model originally due to Kaplan (1989, Rev. Inf. Diseases 11, 289-98). They start off
with a brief literature survey and review; this is followed up by a detailed description
of Kaplan’s model. They then outline a more realistic extension of Kaplan’s model.
Then they perform an equilibrium and stability analysis on this model. They found
that there is a critical threshold parameter R0 which determines the behaviour of the
model. If R0 ≤ 1 there is a unique disease-free equilibrium, and if R0 < 1 the disease
dies out. If R0 > 1 this disease-free equilibrium is unstable, and in addition there is a
unique endemic equilibrium which is locally stable. If a certain condition is satisfied
(and for Kaplan’s model this condition is always satisfied), additional complete global-
stability results are shown. They confirmed these results and explored them further
via simulations.
Williams and Anderson [80] considered a mathematical model of the transmission
dynamics of the HIV-1 in England and Wales. The model mimics transmission within
and between different sexual activity classes (or needle sharing classes in the case of
intravenous drug users) and within and between different risk groups such as male
homosexuals, intravenous drug users and heterosexuals. They described the patterns
of mixing and sexual contact by mixing matrices whose elements define the degree of
assortative or disassortative contact between different stratifications of the sexually
active population.
The parameters that the above authors used were based on published data but
likely patterns of mixing are crudely estimated by fitting model projections to past
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temporal trends in the incidence of AIDS in the different at-risk groups in England and
Wales. They shown many different parameter combinations fitting past trends and
explained that each has different implications for projections into the future. The also
highlighted the importance of mixing patterns to future trends. They concluded that
future trends are uncertain (on the basis of current information) particularly within
the heterosexual population. Small changes in the values of key parameters induce
significant changes in projected trends. They also indicated that the transmission
models are of greatest value as tools to highlight needs for data for accurate projection
and as a template for assessing the relative contribution of various factors to future
trends in the incidence of AIDS.
Porco and Blower [68] developed and used mathematical models to assess vaccine
programs for controlling two subtypes of HIV, both for developing countries where
more than one subtype is present and for countries where only one subtype is present
but other subtypes may invade. They began by formulating a model of the intrinsic
transmission dynamics of the two HIV subtypes and then extended this model to
include the effects of a prophylactic vaccine that provides a degree of protection
against infection by one subtype and vaccine-induced cross-immunity against infection
by the second subtype. Using these models, they assessed the potential impact of
using a prophylactic vaccine when one subtype of HIV is endemic and a second
subtype is introduced into the community. In each case, mass vaccination could
result in one of four possible outcomes: (1) both subtypes are eradicated, (2) the
endemic subtype persists and the invading subtype is eradicated, (3) the endemic
subtype is eradicated and the invading subtype persists, or (4) both subtypes coexist.
In [69], Raab et al. described the methodology developed to carry out predictions
of the AIDS epidemic in Scotland. Information on the HIV epidemic comes from
formal case reports of AIDS cases and HIV positive tests, reports from surveillance
schemes and from special studies. They reviewed these sources of information, upto
the end of 1994. Prior information on aspects of HIV disease is available from various
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published and unpublished sources. They proposed a simple model of the HIV epi-
demic in Scotland and the information is summarized in terms of this model. Using
the Monte Carlo methods, the Bayesian methodology is described and used to predict
future cases of AIDS in Scotland.
Tuckwella and Le Corfecb [76] developed a simple stochastic mathematical model
and investigated for early HIV-1 population dynamics. Their model, which is a multi-
dimensional diffusion process, includes activated uninfected CD4 T-cells, latently and
actively infected CD4 T-cells and free virions occurring in plasma. They assumed
that the stochastic effects will arise in the process of infection of CD4 T-cells and
transitions may occur from uninfected to latently or actively infected cells by chance
mechanisms. Using the then available parameter values, they examined the intrinsic
variability in response to a given initial infection by solving the stochastic system
numerically. They estimated the statistical distributions of the time of occurrence
and the magnitude of the early peak in viral concentration.
For many years compartmental models have provided useful insights into the
spread of epidemics. Such models are usually fairly easy to set up, but even the
simpler models have the disadvantage that they are intractable to analytic solution.
In [36] Griffiths et al. examined models of the HIV/AIDS epidemic, and showed
that the equations may be linearized in a piecewise manner over time, thus allowing
analytic solutions to be obtained. Indications of the usefulness of this approach are
provided. In particular, an analytic solution gives insight into the mechanism of the
epidemic, together with a clearer picture of the sensitivity of results to changes in pa-
rametervalues. Further, the processes of parameter estimation and the methodology
of back-calculation also benefit from the provision of functional forms for the state
variables.
In the paper by Lenbury et al. [52], geometric singular perturbation arguments
are utilized to develop a separation condition for the identification of limit cycles
in higher-dimensional (n ≥ 4) dynamical systems characterized by highly diversified
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time responses, in which there exists a three-dimensional subsystem which quickly
reaches a quasi-steady state. The condition, which has been used until then to analyze
relaxation oscillation in slow-fast systems, was extended to accommodate dynamical
systems in which more state variables are involved in a special manner that still allows
for the use of singular perturbation techniques. Application is then made to a model
of HIV infection in T helper (TH) cell clones with limiting resting TH cell supply.
Porco and Blower [67] analyzed a mathematical model of the simultaneous trans-
mission of two HIV subtypes and their control by vaccines. Two vaccines are an-
alyzed which utilize different mechanisms, one in which the vaccine take differs for
each subtype, and the other in which a different level of reduced infectivity results
after infection by each subtype. The equilibrium outcome is different for each case;
equilibrium coexistence of the two subtypes is possible in the differential take model,
but not in the differential reduced infectivity model. This was the first step in un-
derstanding the interaction of HIV subtypes and differentially effective vaccines with
different modes of action.
In [19] Coutinho et al. considered the variation of viraemia in the natural course
of HIV infection which is expected to have major influence on the probability of
transmission and, consequently, on the epidemiology of HIV/AIDS. In this paper
they proposed a model which takes into account the time evolution of HIV viraemia
(measured as HIV-RNA copies per ml of blood) in an infected individual and its
impact on the threshold for the establishment of an endemic level, and mainly on
the relative contribution of each of the clinical phases of the infection to the total
transmission of HIV per infected individual.
Coutinho et al. [19] considered that an infected individual passes through three
phases of viraemia. The first phase, which lasts for 6-7 weeks, is characterized by
very high viraemia. In the second phase, which lasts about 10 years, the viraemia is
much lower, increasing again in the last phase, which lasts up to two years, and ends
in full-blown AIDS. They showed that the relative contribution of each phase to the
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total transmission of HIV is very sensitive to the model they assumed for the depen-
dence of the transmissibility of HIV on the viral load. For instance, if they assume
that transmissibility is proportional to the decimal logarithm of viraemia, then the
second phase predominates always. They indicated that due to the epidemiological
importance of this fact, further improvement on virological research to better under-
stand the dependence of HIV transmissibility on the viral concentration in biological
fluids is necessary.
Callaway and Perelson [18] showed that HAART (highly active antiretroviral ther-
apy) reduces the viral burden in HIV-1 infected patients below the threshold of de-
tectability. However, substantial evidence indicates that viral replication persists in
these individuals. In this paper they examined the ability of several biologically mo-
tivated models of HIV-1 dynamics to explain sustained low viral loads. At or near
drug efficacies that result in steady state viral loads below detectability, most models
are extremely sensitive to small changes in drug efficacy. They argued that if these
models reflect reality many patients should have cleared the virus, contrary to obser-
vation. They found that a model in which the infected cell death rate is dependent on
the infected cell density does not suffer this shortcoming. The shortcoming was also
overcomed in two more conventional models that include small populations of cells in
which the drug is less effective than in the main population, suggesting that difficulties
with drug penetrance and maintenance of effective intracellular drug concentrations
in all cells susceptible to HIV infection may underlie ongoing viral replication.
Ribeiro et al. [72] showed that HIV-1 infects cells of the immune system and
leads to depletion of CD4+ T-cells, and to an increase of CD8+ T-lymphocytes.
They mentioned that not much is known about the dynamics of turnover (prolifer-
ation and death) of the CD4+ and CD8+ T-cell populations in HIV-infected and
healthy individuals. Using deuterated-glucose labeling, they developed a new exper-
imental technique that provides information on cell turnover in vivo. However, the
quantitative interpretation of the data requires the development of specific dynamic
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models. In this paper they derive two models, a simple one-compartment model and
a more complex two-compartment model. These models allow for robust quantifica-
tion of death and proliferation rates. They demonstrated that more realistic models
can account not only for differences in the turnover rates between HIV-infected and
healthy individuals, but also take into consideration the elevated state of activation
in HIV infection. The use of these models in the interpretation of the experimental
data certainly increases one’s knowledge of T-cell dynamics in the context of HIV
infection.
Diaz et al. [23] designed anti-HIV compounds which has now become a crucial
area for scientists working in numerous interrelated fields of science such as molecular
biology, medicinal chemistry, mathematical biology, molecular modelling and bio-
informatics. In this context, the development of simple but physically meaningful
mathematical models to represent the interaction between anti-HIV drugs and their
biological targets is of major interest.
Above authors applied Markov chain theory in an attempt to describe the inter-
action between the antibiotic paromomycin and the packaging region of the RNA
in Type-1 HIV. In this model, they used a nucleicacid squeezed graph. The ver-
tices of the graph represent the nucleotides while the edges are the phosphodiester
bonds. A stochastic (Markovian) matrix was subsequently defined on this graph, an
operation that codifies the probabilities of interaction between specific nucleotides of
HIV-RNA and the antibiotic. The strength of these local interactions can be cal-
culated through an inelastic vibrational model. The successive power of this matrix
codifies the probabilities with which the vibrations after drug-RNA interactions van-
ish along the polynucleotide main chain. The sums of self-return probabilities in the
k-vicinity of each nucleotide represent physically meaningful descriptors. A linear
discriminant function was developed and gave rise to excellent discrimination in 80.8
% of interacting and footprinted nucleotides. They employed the Jack-knife method
to assess the stability and predictability of the model. On the other hand, a linear
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regression model predicted the local binding affinity constants between a specific nu-
cleotide and the antibiotic (R(2) = 0.91, Q(2) = 0.86). These kinds of models could
play an important role either in the discovery of new anti-HIV compounds or the
study of their mode of action.
Percus et al. [65] mentioned that in HIV-1 infected patients, the treatment with
combination antiretroviral therapy frequently have the level of HIV-1 RNA detectable
in plasma driven below the lower limit of detection of current, 50 copies ml(-1).
Patients may continue to exhibit viral loads (VLs) below the assay limit for years, yet
on some occasions the VL may be above the limit of detection. Whether these ‘blips’
in VL are simply assay errors or are indicative of intermittent episodes of increased
viral replication is of great clinical concern. By analyzing the occurrence of viral
blips in 123 treated HIV-infected patients, they showed that patients do not share
a common probability distribution of blip amplitude and thus reject the hypothesis
that blips are solely due to assay variation.
In [14] Bortz and Nelson performed a formal sensitivity analysis on a delay dif-
ferential equation model for the viral dynamics of an in vivo HIV infection during
protease inhibitor therapy. They presented results of both a differential analysis as
well as a principle component based analysis and provided evidence that suggests
the exact times at which specific parameters have the most influence over the so-
lution. They offer insight into the pairwise mathematical relationships between the
productively infected T-cell death rate delta, the viral plasma clearance rate c, and
the time delay τ between infection and viral production as they relate to the viral
dynamics. The results support the claim that the presence of a nonzero delay has a
major impact on the model dynamics. Lastly, they comment upon the inadequacies
of an alternative principle component based analysis.
A theoretical model was proposed by Hsien and Chen [42] for a community which
has the structure of two classes (direct and indirect) of commercial sex workers (CSW),
and two classes of sexually active male customers with different levels of sexual ac-
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tivity. The direct CSW’s work in brothels while the indirect CSW’s are based in
commercial establishments such as bars, cafes, and massage parlours where sex can
be bought on request and conducted elsewhere. Behaviour change and the resulting
change of activity class occurs between the two classes of CSW’s and two classes of
males under the setting of the proliferation of HIV/AIDS epidemic and the subsequent
intervention programmes.
In recent years, this phenomenon has been observed in several countries in Asia.
Given the lowerlevels of condom use and higher HIV prevalence of the indirect CSW’s,
ascertaining the impact of this change in the structure of the sex industry on the
spread of HIV is the main focus of their paper. They gave the complete analysis of
the disease-free model. For the full model, local analysis was performed for the case
of preferred mixing without activity class change, as well as the case with activity
class change and restricted mixing. The basic reproduction number for the spread
of epidemic was derived for each case. Results of biological significance include:
(i). the change of behaviour by the CSW’s has a more direct effect on the spread
of HIV than that of the male customers; (ii). the basic reproduction number is
obtained by considering all possible infection cycles of the heterosexual transmission
of HIV which indicates the importance of understanding the sexual networking in
heterosexual transmission of HIV; (iii). the social dynamics of the sex industries.
In [44] Jafelice et al. paper introduced a model for the evolution of positive
HIV population and manifestation of AIDS. The focus was on the nature of the
transference rate of HIV to AIDS. Expert knowledge indicates that the transference
rate is uncertain and depends strongly on the viral load and the CD4+ level of the
infected individuals. Here, they suggest to view the transference rate as a fuzzy set
of the viral load and CD4+ level values. In this case the dynamic model results in
a fuzzy model that preserves the biological meaning and nature of the transference
rate. Its behavior fits the natural history of HIV infection reported in the medical
science domain. The paper also includes a comparison between the fuzzy model and
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a classic Anderson’s model using data reported in the literature.
Gumel et al. [38] investigated a class of finite-difference methods, designed via
the non-standard framework of Mickens, for solving Model-IV described in previous
subsection. They shown that this class of methods can often give numerical results
that are asymptotically consistent with those of the corresponding continuous model.
Hewer and Meyer [40] presented a major problem impeding the development of
an effective HIV-1 vaccine is the rapid antigenic variability that occurred throughout
the viral genome. They indicated that the high number of errors made by the reverse
transcriptase (RT) enzyme and the absence of an RT proofreading mechanism during
HIV-1 replication leads to new antigenic variants that escape current immunological
attack. In turn, accumulation of escape mutants leads to a persistent infection. It
has been hypothesized through many means including mathematical modeling that
preventing HIV persistence necessitates a vaccine that enhances immunity against
a sufficiently large fraction of mutant stains. To this extent they have developed a
4 branched and an 8 branched multiple epitope immunogen (MEI) that in theory
represent 6.7107 and 1.81016 envelope V3 loop sequences respectively. Both MEI
constructs were recognized by antibodies in sera from AIDS and/or HIV-1 positive
patients from South Africa and Puerto Rico. The immunogens also induced immune
responses in MF1 mice and New Zealand White rabbits with the octameric MEI prov-
ing to be a more effective antigen. This data supports our hypothesis that synthetic
peptides designed to represent the variable regions of HIV-1 envelope should induce
immunity against a large quantity of mutant strains.
In [46] Jonesa and Perelson explained that when highly active antiretroviral ther-
apy is administered for long periods of time to HIV-1 infected patients, most patients
achieve viral loads that are “undetectable” by standard assay (i.e., HIV-1 RNA < 50
copies/ml). Yet despite exhibiting sustained viral loads below the level of detection,
a number of these patients experience unexplained episodes of transient viremia orvi-
ral “blips”. They proposed here that transient activation of the immune system by
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opportunistic infection may explain these episodes of viremia. Indeed, immune acti-
vation by opportunistic infection may spur HIV replication, replenish viral reservoirs
and contribute to accelerated disease progression.
In order to investigate the effects of intercurrent infection on chronically infected
HIV patients under treatment with highly active antiretroviraltherapy, the above
two authors extended a simple dynamic model of the effects of vaccination on HIV
infection (Jones, L.E., Perelson, A.S., 2002. Modeling the effects of vaccination on
chronically infected HIV-positive patients. JAIDS 31, 369-377) to include growing
pathogens. Then they proposed a more realistic model for immune cell expansion in
the presence of pathogen, and included this in a set of competing models that allow
low baseline viral loads in the presence of drug treatment. They also mentioned that
programmed expansion of immune cells upon exposure to antigen is a feature not
previously included in HIV models, and one that is especially important to consider
when simulating an immune response to opportunistic infection. Using these models
they showed that viral blips with realistic duration and amplitude can be generated
by intercurrent infections in HAART treated patients.
Snedecor [74] considered some recent advances in the chemotherapy of HIV infec-
tion that have been successful in delaying the progression of disease in many patients
and are responsible for the decline in HIV-related deaths in the United States. It is
mentioned in this article that there are many patients who fail to maintain suppressed
viral loads on treatment. Means to extend the utility of currently available drugs in-
clude developing improved ways to assess the therapeutic impact of drug-resistant
variants.
A mathematical model to incorporate the presence of resistance mutations with
either primary or secondary classifications was created as a means to explore the
association between phenotypic resistance and duration of viral response to therapy.
The model, which includes phenotypic and genotypic resistance information for each
viral mutant, was presented with a simplified five-codon genome. The analysis in
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this paper suggests that, in the model, the resistance phenotypes of the strains with
an intermediate number of mutations are the primary determinants of both the total
duration of viral suppression with a single treatment and the difference between the
durations of suppression of the forward and reverse sequential administrations of two
treatments. These findings implied that a model including the resistance phenotype
and in vivo response of genotypically-resistant viral strains may lead to a priori predic-
tion of successful anti-HIV drug selection for an individual harboring drug-resistant
virus.
Hsieh and Wang [43] noticed that the basic reproduction number is obtained for
an HIV epidemic model incorporating direct and indirect commercial sex as well
as behavior change by the female commercial sex workers (CSWs) and their male
customers in response to the proliferation of the disease in the community. Using
the work of van den Driessche P., and Watmough J. (Math. Biosci. 180:29-48,
2002), they computed the threshold parameters for the local asymptotic stability of
the Disease-Free Equilibrium (DFE), by considering the transfers in and out of the
infective classes.
Hsieh and Wang in the above work used numerical examples to describe the
uniqueness and global properties of the endemic equilibrium when DFE is unstable
and discussed the implications of the results for the design of public health policies
such as targeting strategy to target intervention and control measures toward specific
high-risk population groups in order to reduce infections. They showed that targeting
any one sector of the commercial sex alone for prevention will be difficult to have a
decided effect on eradicating the epidemic. However, if the aim of the targeted inter-
vention policy is not eradication of the epidemic but decrease in HIV incidence of a
particular high-risk group, then concentrated targeting strategy could be sufficient,
if properly implemented. They also demonstrated the usefulness of the theorem of
van den Driessche and Watmough in obtaining threshold parameters for complicated
infectious diseases models.
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In [78] Laera et al. presented previous clinical trials in previous HIV-infected
patients involving infusion of T-cells protected by an antiviral gene that failed to
show any therapeutic benefit. They mentioned that the value of such a treatment
approach is still highly controversial. In this study, they analyzed the anticipated
effects of gene-modifiedcells on virus and T-cell kinetics. Because technically only
a small fraction of all T-cells in a patient can be manipulated ex vivo, therapeutic
success will depend on the accumulation of gene-modified cells after infusion into the
patient by in vivo selection. Their simulations predicted that a significant therapeutic
benefit is conferred only by antiviral genes that inhibit previous HIV replication before
virus integration (class I genes). Genes that inhibit viral protein expression (class II,
used in previous clinical trials), require a much higher inhibitory activity than class I
genes to promote the regeneration of T-cells and reduce the viral load. They further
indicated that in determining the clinical outcome the regenerative capacity of the
gene-modified cells and the level of previous HIV replication in the patient are crucial.
These results can be important for guiding future strategies in the field of gene therapy
for previous HIV infection.
Besides the above mentioned works, the readers may find the articles [15, 21, 34,
39, 51] further relevant to the subject.
Based on the above descriptions and survey, we decided to work on the model
that has two HIV subtypes. Such a model is analyzed in Chapter 2 and some nu-
merical methods are developed and analyzed for this model in Chapter 3. Chapter 4
contains the comparative numerical results obtained with various methods presented
in Chapter 3. Summery of the thesis and some concluding remarks indicating our
future research plans are given in Chapter 5.
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Chapter 2
Analysis of the model governing
the transmission dynamics of two
HIV-subtypes
Our aim is to construct some reliable numerical methods for relevant HIV model(s).
In order for us to be able to design these numerical methods, it is essential that we
look at the qualitative properties of the model(s). To this end, in this chapter we
analyse the following model (referred to as Model IV in Chapter 1) given by the set
of differential equations (1.7)-(1.10) which deals with the “Transmission Dynamics of
two HIV subtypes” [37] in a given community.
2.1 Disease Free Equilibrium
The Disease Free Equilibrium (DFE) (X∗ 6= 0, V ∗ 6= 0, Y ∗1 = 0, Y
∗
2 = 0) corresponding
to this model is obtained by solving
Π(1− ρ)− µX∗ = 0, (2.1)
Πρ− µV ∗ = 0 (2.2)
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which gives
(X∗, V ∗, Y ∗1 , Y
∗
2 ) =
(
Π(1− ρ)
µ
,
Πρ
µ
, 0, 0
)
. (2.3)
2.2 Stability of the Disease Free Equilibrium
The Jacobian corresponding to (1.7)-(1.10) is given by
J(X,V, Y1, Y2) =

−µ− β1cY1
N
− β2cY2
N
0 −β1cX
N
−β2cX
N
0 −µ− (1−ξ1)β1cY1
N
− (1−ξ2)β2cY2
N
− (1−ξ1)β1cV
N
− (1−ξ2)β2cV
N
β1cY1
N
(1−ξ1)β1cY1
N
J33 0
β2cY2
N
(1−ξ2)β2cY2
N
0 J44


(2.4)
where
J33 =
β1cX
N
+
(1− ξ1)β1cV
N
−(µ+γ1+τ) and J44 =
β2cX
N
+
(1− ξ2)β2cV
N
−(µ+γ2+τ).
Evaluating the above Jacobian at the DFE, we obtain
JDFE ≡ J(X
∗, V ∗, Y ∗1 , Y
∗
2 ) =


−µ 0 −β1cX
∗
N
−β2cX
∗
N
0 −µ − (1−ξ1)β1cV
∗
N
− (1−ξ2)β2cV
∗
N
0 0 J∗33 0
0 0 0 J∗44


, (2.5)
where
J∗33 =
β1cX
∗
N
+
(1− ξ1)β1cV
∗
N
−(µ+γ1+τ) and J
∗
44 =
β2cX
∗
N
+
(1− ξ2)β2cV
∗
N
−(µ+γ2+τ).
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Using (2.3) along with (2.5) and the fact that the matrix in (2.5) is triangular, the
eigenvalues (denoted by λi, i = 1, 2, 3, 4) are precisely the diagonal entries. Thus
λ1 = −µ,
λ2 = −µ,
λ3 = β1c(1− ρξ1)− (µ+ γ1 + τ),
λ4 = β2c(1− ρξ2)− (µ+ γ2 + τ).


(2.6)
(Note in the above that as t→∞, dN/dt→ 0 which means that N → Π/µ.)
Since µ is positive, it is evident now from the above equation that both λ1 and λ2
are negative whereas
λ3 < 0 if β1c(1− ρξ1) < (µ+ γ1 + τ), i.e.
β1c(1− ρξ1)
(µ+ γ1 + τ)
< 1.
Similarly,
β1c(1− ρξ1)
(µ+ γ1 + τ)
and
β2c(1− ρξ2)
(µ+ γ2 + τ)
are respectively, denoted by, R
(1)
ρ and R
(2)
ρ , and are called the reproduction numbers.
We therefore have the following result about the local asymptotic stability of the
disease-free equilibrium.
Lemma 2.1. The disease-free equilibrium of the HIV model is locally asymptotically
stable if R0= max
{
R
(1)
ρ , R
(2)
ρ
}
< 1.
Remark 2.2. This lemma shows that a small flow of HIV infected individuals into
the community would not result in a major epidemic provided R0 < 1. Furthermore,
We found that the disease-free equilibrium of HIV model under consideration is locally
asymptotically stable if the reproduction number for both of the subtypes is less
than unity. This means that a small influx of HIV-infected individuals into the
community would not result in a major epidemic provided that the maximum of the
two reproduction numbers is less than unity.
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• When both reproduction numbers exceeds unity, the subtype with the higher
reproduction number eventually overcomes the other and becomes the only
existing HIV subtype at steady state.
• The two subtypes co-exist if the two reproduction numbers are equal and greater
than unity.
This information provided in the above remark will be useful in designing suitable
numerical methods.
We have shown that HIV will persist (or be established in the community) if and
only if at least one of the two eigenvalues of the associated Jacobian matrix has a
positive real part (so that the maximum of the two reproduction number will be
greater than unity). For a general discussion on the stability analysis, the readers are
referred to Appendix C.
Remark 2.3. Adding the four equations (1.7-1.10), we obtain
dN
dt
= Π− µ(X + V )− (µ+ γ1 + τ)Y1 − (µ+ γ2 + τ)Y2.
Therefore, if there are no sub-types, then the total population will be N = X + V
meaning that
N → Π− µ(X + V ) as t→∞.
Hence the following feasible region:
D =
{
(X, V, Y1, Y2) ∈ R
4
+ : X + V + Y1 + Y2 ≤ Π/µ
}
,
is positively invariant. It is therefore sufficient to consider the solution of (1.7-1.10)
in D.
Theorem 2.4. The disease-free equilibrium of the HIV model is globally asymptoti-
cally stable if R0= max
{
R
(1)
ρ , R
(2)
ρ
}
< 1.
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Proof. We consider the Lyapunov functions V1 = Y1 and V2 = Y2 which have the
following Lyapunov derivatives
V˙1 =
[
β1cX
N
+
(1− ξ1)β1cV
N
− (µ+ γ1 + τ)
]
Y1
=
[
β1c
N
(1− ρ)Π
µ
+
(1− ξ1)β1c
N
− (µ+ γ1 + τ)
]
Y1
= (µ+ γ1 + τ)
(
R(1)ρ − 1
)
Y1
≤ 0 for R(1)ρ ≤ 1. (2.7)
Similarly,
V˙2 ≤ 0 for R
(2)
ρ ≤ 1. (2.8)
Therefore, using the Lyapunov stability theorem (see Appendix C), the DFE is glob-
ally asymptotically stable under the condition R0= max
{
R
(1)
ρ , R
(2)
ρ
}
< 1.
2.3 Other Equilibria
The procedure for finding the other equilibria, viz.,
• subtype-1 only equilibrium
• subtype-2 only equilibrium
• co-existing equilibrium
is similar to the one we described above and the Jacobian matrix given in (2.4) can
be evaluated on these equilibria. The resulting eigenvalues can then provide relevent
constraints. However, the closed form solutions (from the equations providing these
three equilibria) are not easily obtainable due to the presense of nonlinearities and
the other sophesticated tools to do so are beyond the scope of this thesis. However,
the interested readers may wish to find some clues via the theory of Gro¨bner basis
[20].
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Chapter 3
Numerical Methods for Model-IV
In this chapter we present some numerical methods for Model-IV described by the
equations (1.7)-(1.10) in Chapter 1. We then give analysis for some of these methods.
The comparative numerical results for all these methods will be provided in the next
chapter.
It is known that the standard methods do not perform well due to unstable solution
profiles for the type of problems we are dealing with and the usual option initially is
left on choosing an implicit method which can stablize the procedure. Taking this fact
into account, there is no point in considering any explicit finite difference method.
We rather consider an Implicit Finite Difference Method (IFDM). We do fixed-point
analysis of this method and found the conditions for stability. Later in next chapter,
we see through numerical illustrations that this method does not preserve positivity
property (a very important and essential property that is expected for many models in
population biology). To overcome this drawback, a novel numerical method (initially
presented in Gumel et al. [38]) referred to as non-standard finite difference method
(NSFDM) is discussed in details. The aspects associated with order of convergence
are also addressed. It is shown that this in transient dynamics, the NSFDM does not
have extraneous solutions unlike IFDM and therefore it is dynamically consistent in
the sense of [59, 30].
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To start with, we fix some notations. The time interval t ≥ 0 is discretized in a
standard way by means of points tn = nℓ, where n = 0, 1, 2, ..., and ℓ denote the time
step-size. The solution of this model (i.e., (1.7)-(1.10)) at tn is denoted by X(tn),
V (tn), Y1(tn), Y2(tn).
3.1 Implicit Finite Difference Method
Using the forward difference approximations for the first derivative terms, we obtain
the following Implicit Finite Difference Method (IFDM) for each of the equations
(1.7)-(1.10)
Xn+1 −Xn
ℓ
= Π(1− ρ)− µXn+1 −
β1cY
n
1 X
n+1 + β2cY
n
2 X
n+1
Xn + V n + Y n1 + Y
n
2
, (3.1)
V n+1 − V n
ℓ
= Πρ− µV n+1 −
(1− ξ1)β1cY
n
1 V
n+1 + (1− ξ2)β2cY
n
2 V
n+1
Xn+1 + V n + Y n1 + Y
n
2
, (3.2)
Y n+11 − Y
n
1
ℓ
=
β1cY
n+1
1 X
n+1 + (1− ξ1)β1cY
n+1
1 V
n+1
Xn+1 + V n+1 + Y n1 + Y
n
2
− (µ+ γ1 + τ)Y
n+1
1 , (3.3)
Y n+12 − Y
n
2
ℓ
=
β2cY
n+1
2 X
n+1 + (1− ξ2)β2cY
n+1
2 V
n+1
Xn+1 + V n+1 + Y n+11 + Y
n
2
− (µ+ γ2 + τ)Y
n+1
2 . (3.4)
The method consisting of (3.1)-(3.4) is referred to as the Implicit Finite Difference
Method (IFDM). The method is first order accurate (as is evident from the numerical
results provided in the next Chapter).
Remark 3.1. The IFDM is implicit by construction, but the terms can be re-arranged
in order to have explicit expressions (fortunately in this case) so as to solve it via an
iterative procedure, i.e.,
Xn+1 =
Xn +Πℓ(1− ρ)
1 + ℓ
[
µ+
c(β1Y n1 +β2Y n2 )
Xn+V n+Y n
1
+Y n
2
] , (3.5)
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V n+1 =
V n +Πℓρ
1 + ℓ
{
µ+
c[(1−ξ1)β1Y n1 +(1−ξ2)β2Y n2 ]
Xn+1+V n+Y n
1
+Y n
2
} , (3.6)
Y n+11 =
Y n1
1 + ℓ
{
µ+ γ1 + τ −
β1c[Xn+1+(1−ξ1)V n+1]
Xn+1+V n+1+Y n
1
+Y n
2
} , (3.7)
Y n+12 =
Y n2
1 + ℓ
{
µ+ γ2 + τ −
β2c[Xn+1+(1−ξ2)V n+1]
Xn+1+V n+1+Y n+1
1
+Y n
2
} . (3.8)
3.1.1 Analysis of the Implicit Finite Difference Method
Denoting the right hand sides of equations (3.5)-(3.8) by fi(X
n, V n, Y n1 , Y
n
2 ), (i =
1, 2, 3, 4), we have the relations
Xn+1 = f1(X
n, V n, Y n1 , Y
n
2 ), (3.9)
V n+1 = f2(X
n, V n, Y n1 , Y
n
2 ), (3.10)
Y n+11 = f3(X
n, V n, Y n1 , Y
n
2 ), (3.11)
Y n+12 = f4(X
n, V n, Y n1 , Y
n
2 ). (3.12)
Furthermore, we denote the equilibrium solution profile by (X∗, V ∗, Y ∗1 , Y
∗
2 ).
3.1.1.1 The Disease Free Equilibrium of Implicit Finite Difference Method
The DFE is obtained by solving the fixed-point problem as follows.
Substituting Y ∗1 = 0 and Y
∗
2 = 0 in the equations obtained from (3.9)-(3.12) af-
ter substituting Z∗ both for Zn+1 and Zn (where Z is X, V, Y1 and Y2). Thus we
obtain the DFE as
(X∗, V ∗, Y ∗1 , Y
∗
2 ) =
(
Π(1− ρ)
µ
,
Πρ
µ
, 0, 0
)
. (3.13)
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3.1.1.2 Subtype-1, Subtype-2 and Co-existing Equilibria for the Implicit
Finite Difference Method
The fixed points of subtype-1 only equilibrium, subtype-2 only equilibrium and the
coexisting equilibrium are more complicated than that of the disease free equilibrium.
This is because all three cases involves nonlinear equations. One option that one could
consider here is to focus on the nonlinear root finding problems.
Remark 3.2. When one deals with the numerical methods, (s)he, at first, checks
whether the “fixed-points” of the numerical methods coincide with the “critical points”
of the continuous problem. The ultimate aim that one has is to check whether the
method provides converging solution profiles and if such a convergence takes place
then under what conditions? The role of this fixed-points is merely to provide the
critical step-sizes that one requires to ensure the stability of the scheme. Unlike
the case of DFE, in this case therefore, not much can be learnt analytically about
these fixed-points and therefore the convergence of the method can be judged through
“Double Mesh Principle”.
3.1.1.3 Convergence of the Implicit Finite Difference Method
Consider equation (3.1).
The Taylor series expansion of Xn+1 about t = tn gives,
Xn+1 = Xn + ℓX˙n +
ℓ2
2!
X¨n + ... (3.14)
Also, from (1.7), we obtain at tn
X˙n = Π(1− ρ)− µXn −
1
N
β1cY
n
1 X
n −
1
N
β2cY
n
2 X
n. (3.15)
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Using (3.14) and (3.15) into (3.1), we get the truncation error of the method (3.1)
to approximate X as
τ(X) =
(
X¨
2
+
(
µ+
β1cY1 + β2cY2
N
)
X˙
)
ℓ2 +O(ℓ3). (3.16)
Hence the method (3.1) is of order one.
A similar approach applied to the methods (3.2), (3.3) and (3.4) (the methods for
V , Y1, Y2), respectively, yields
τ(V ) =
[
V¨
2
+ µV˙ −
(
c [(1− ξ1)β1Y1 + (1− ξ2)β2Y2] X˙
N
)
V
]
ℓ2
+O(ℓ3), (3.17)
τ(Y1) =
[
Y¨1
2
+
(
(µ+ γ1 + τ)−
{β1c(X + (1− ξ1))V }
N
)
Y˙1
+
(
{(X + (1− ξ1)V )}
(
X˙ + V˙
)
− {X˙ + (1− ξ1)V˙ }
) β1c
N
Y1
]
ℓ2
+O(ℓ3) (3.18)
and
τ(Y2) =
[
Y¨2
2
+
(
(µ+ γ2 + τ)−
{β2c(X + (1− ξ2))V }
N
)
Y˙2
+
(
{(X + (1− ξ2)V )}
(
X˙ + V˙ + Y˙1
)
− {X˙ + (1− ξ2)V˙ }
) β2c
N
Y2
]
ℓ2
+O(ℓ3) (3.19)
which means that these are also first order accurate.
As can be seen from the convergence estimates (3.16)-(3.19), the IFDM is only
first-order accurate and that too under severe restrictions on step-size (such a restric-
tion can be found by a more detailed analysis). This means that one requires a large
number of iterations to generate the accurate solution profile. Hence, it is a good idea
to consider higher order methods. To this end, we consider below the fourth-order
Runge-Kutta Method.
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3.2 Runge-Kutta Method of Order Four
The Runge-Kutta method of order four (RK4) for the system of equations (1.7)-(1.10)
can be described as follows:
Given the initial conditions
X(t0) = X
0, V (t0) = V
0, Y1(t0) = Y
0
1 , and Y2(t0) = Y
0
2 ,
we assume that the values X1,j, V 1,j , Y 1,j1 , Y
1,j
2 have been computed, where j =
0(1)n. We then obtain X1,j+1, V 1,j+1, Y 1,j+11 , Y
1,j+1
2 in the following manner: For
each i = 1(1)4, we calculate
k1,i = ℓfi
(
tj , X
1,j, V 1,j , Y 1,j1 , Y
1,j
2
)
, (3.20)
k2,i = ℓfi
(
tj +
ℓ
2
, X1,j +
k1,1
2
, V 1,j +
k1,2
2
, Y 1,j1 +
k1,3
2
, Y 1,j2 +
k1,4
2
)
, (3.21)
k3,i = ℓfi
(
tj +
ℓ
2
, X1,j +
k2,1
2
, V 1,j +
k2,2
2
, Y 1,j1 +
k2,3
2
, Y 1,j2 +
k2,4
2
)
, (3.22)
k4,i = ℓfi
(
tj + ℓ, X
1,j + k3,1, V
1,j + k3,2, Y
1,j
1 + k3,3, Y
1,j
2 + k3,4
)
, (3.23)
where f1 = X, f2 = V , f3 = Y1 and f4 = Y2 in the above.
Then we compute
wi,j+1 = wi,j +
1
6
(k1,i + 2k2,i + 2k3,i + k4,i) , (3.24)
where wi,j stands for X
j, V j , Y j1 and Y
j
2 when i is respectively, 1, 2, 3 and 4.
Though tedius, but one can check that like the IFDM, the above method (RK4)
is also not free of step-size restrictions. Since in the population biology, one might
require the information at various time levels, one need to have flexibilities in choos-
ing the step-sizes. To this end, we consider below another class of finite difference
methods, termed as Non standard Finite Difference Method (NSFDM). Even though
this NSFDM is only first order accurate, it is free of step-size restrictions. Moreover,
unlike IFDM and RK4, this method always provides positive solutions and hence it
is dynamically consistent.
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3.3 Non-Standard Finite Difference Method
One can see that Y n+11 and Y
n+1
2 (respectively, in (3.7) and (3.8) has negative de-
nominators, because of the approximation of the terms in equations (1.9) and (1.10)
which might cause problems as they will contribute towards negative profile of the
solution. This has occured due to the following:
The terms
β1cXY1
N
and
(1− ξ1)β1cV Y1
N
in (1.9) are approximated by
β1cX
n+1Y n+11
Xn+1 + V n+1 + Y n1 + Y
n
2
(3.25)
and
(1− ξ1)β1cV
n+1Y n+11
Xn+1 + V n+1 + Y n1 + Y
n
2
. (3.26)
respectively. A similar approach was used for the terms
β2cXY2
N
and
(1− ξ2)β2cV Y2
N
in (1.10).
To overcome this drawback, we use the non-local approximation for those terms
as follows.
We construct the two methods for Y1 and Y2, which must preserve the positivity
property of the model. The variables Y1 and Y2 in the first two terms of the equations
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dY1
dt
and dY2
dt
of the HIVModel IV, are respectively, approximated using their non-local
representations given below
Y1 → 2Y
n
1 − Y
n+1
1 and Y2 → 2Y
n
2 − Y
n+1
2 . (3.27)
(It should be noted that the methods of X and V do not have negative solutions for
0 < ξ1, ξ2 < 1 in (3.1)-(3.2), we need only to ensure that the methods Y1 and Y2
preserve positivity.)
Thus we have the following methods for Y1 and Y2
Y n+11 − Y
n
1
ℓ
=
β1cX
n+1(2Y n1 − Y
n+1
1 ) + (1− ξ1)β1cV
n+1(2Y n1 − Y
n+1
1 )
Xn+1 + V n+1 + Y n1 + Y
n
2
− (µ+ γ1 + τ) Y
n+1
1 (3.28)
and
Y n+12 − Y
n
2
ℓ
=
β2cX
n+1(2Y n2 − Y
n+1
2 ) + (1− ξ2)β2cV
n+1(2Y n2 − Y
n+1
2 )
Xn+1 + V n+1 + Y n+11 + Y
n
2
− (µ+ γ2 + τ) Y
n+1
2 . (3.29)
Rearranging Y n+11 and Y
n+1
2 , the non-standard method, referred to as NSFDM, for
solving the HIV-model consists of the equations:
Xn+1 =
Xn +Πℓ(1− ρ)
1 + ℓ
[
µ+
c(β1Y n1 +β2Y n2 )
Xn+V n+Y n
1
+Y n
2
] , (3.30)
V n+1 =
V n +Πℓρ
1 + ℓ
{
µ+
c((1−ξ1)β1Y n1 +(1−ξ2)β2Y n2 )
Xn+1+V n+Y n
1
+Y n
2
} , (3.31)
Y n+11 =
{
1 +
2ℓβ1c[Xn+1+(1−ξ1)V n+1]
Xn+1+V n+1+Y n
1
+Y n
2
}
Y n1
1 + ℓ
{
β1c[Xn+1+(1−ξ1)V n+1]
Xn+1+V n+1+Y n
1
+Y n
2
+ µ+ γ1 + τ
} , (3.32)
Y n+12 =
{
1 +
2ℓβ2c[Xn+1+(1−ξ2)V n+1]
Xn+1+V n+1+Y n+1
1
+Y n
2
}
Y n2
1 + ℓ
{
β2c[Xn+1+(1−ξ2)V n+1]
Xn+1+V n+1+Y n+1
1
+Y n
2
+ µ+ γ2 + τ
} . (3.33)
49
 
 
 
 
Remark 3.3. According to Mickens terminology, these methods are ‘non-standard’
because non-local discretization have been used. The specific rule used above is one
of the few modelling rules set by Mickens [59] and subsequently addressed in several
articles as is mentioned in [64]. For the sake of completeness, we provide these rules
in Appendix B.
3.3.1 Analysis of the Non-Standard Finite Difference Method
3.3.1.1 The Disease Free Equilibrium of the Non-Standard Finite Differ-
ence Method
To find the disease free equilibrium for NSFDM, is the same process as to find disease
free equilibrium for IFDM due to the fact that the equations for Xn+1 and V n+1 are
the same for both methods.
3.3.1.2 Subtype-1, Subtype-2 and Co-existing Equilibria for the Non-
Standard Finite Difference Method
The similar discussion as in the sub-section 3.1.1.2 explains the complexity issues in
calculating these fixed points. Furthermore, generally the aim is to look for the ways
to eradicate/control the disease and for that, the DFE is mostly sufficient.
3.3.1.3 Convergence of the Non-Standard Finite Difference Method
Like the IFDM, the NSFDM is also first order accurate. The procedure for studying
the convergence is analogous to that of the IFDM.
The three methods (IFDM, NSFDM and RK4) described in this chapter are sim-
ulated and compared using the same set of parameter values and initial condition.
The comparative results are provided in next chapter.
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Chapter 4
Comparative Numerical Results
In this chapter we will provide extensive numerical results obtained via various meth-
ods developed for Model IV.
The parameters used in the simulations are µ = 1
32
, Π = 2000, c = 4, γ1 =
0.1, γ2 = 0.1, ξ1 = 0.3, ξ2 = 0.4, ρ = 0.5, τ = 0.4, X(0) = 8000, V (0) = 800, Y1(0) =
200, and Y2(0) = 300 (see [38]).
The two parameters β1 and β2 are chosen in such a way that they give different
reproduction numbers mentioned as per below
(i) β1 = 0.03, β2 = 0.035 ⇒ R
(1)
ρ = 0.1920, R
(2)
ρ = 0.21082. Expected output:
both Subtypes should be eliminated.
(ii) β1 = 0.03, β2 = 0.35 ⇒ R
(1)
ρ = 0.1920, R
(2)
ρ = 2.1082. Expected output:
Subtype-2 should persist.
(iii) β1 = 0.3, β2 = 0.035 ⇒ R
(1)
ρ = 1.920, R
(2)
ρ = 0.21082. Expected output:
Subtype-1 should persist.
(iv) β1 = 0.3, β2 = 0.35 ⇒ R
(1)
ρ = 1.920, R
(2)
ρ = 2.1082. Expected output:
Subtype-2 should invade Subtype-1 meaning that Subtype-2 should persist.
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(v) β1 = 0.35, β2 = 0.3 ⇒ R
(1)
ρ = 2.240, R
(2)
ρ = 1.8071. Expected output:
Subtype-1 should invade Subtype-2 meaning that Subtype-1 should persist.
The above theoretical observation is confirmed with the two numerical methods
(IFDM and NSFDM) and the results obtained by both of them are similar. (In the
table below, note that X∗, V ∗, Y ∗1 , Y
∗
2 denote the equilibrium solutions of different
solution profiles).
Table 4.1: Effect of reproduction numbers, using IFDM/NSFDM/RK-4, ℓ = 0.001
R
(1)
ρ R
(2)
ρ X∗ V ∗ Y ∗1 Y
∗
2
0.1920 0.21082 32000 32000 0 0
0.1920 2.1082 1379 2233 0 3552
1.9200 0.21082 1702 2378 3525 0
1.920 2.1082 1379 2233 0 3552
2.240 1.8071 1270 1785 3585 0
The letters E and C with EX, EV , EY1, EY2 and RX, RV , RY1, RY2 in the table
captions, indicate, respectively, “Error” and “Rate of Convergence” for the particular
compartment. (It should be noted that the errors and the rates of convergence are
obtained by using the well-known double mesh principle [28] as the exact solution is
not available for this model.)
We expect the error to be less for the cases where the particular subtype is expected
to be eliminated.
For figures, the parameters used in the simulations are µ = 1
32
, Π = 2000, c =
4, γ1 = 0.1, γ2 = 0.1, ξ1 = 0.3, ξ2 = 0.4, ρ = 0.5, τ = 0.4, X(0) = 8000, V (0) =
800, Y1(0) = 200, and Y2(0) = 300 as above and β1 = 0.3, β2 = 0.35.
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Table 4.2: Maximum Errors via IFDM for β1 = 0.03, β2 = 0.035
ℓ EX EV EY1 EY2
5.00e-02 4.11e+00 4.63e+00 3.75e-01 5.40e-01
2.50e-02 2.05e+00 2.32e+00 1.89e-01 2.72e-01
1.25e-02 1.03e+00 1.16e+00 9.46e-02 1.36e-01
6.25e-03 5.14e-01 5.79e-01 4.74e-02 6.82e-02
3.13e-03 2.57e-01 2.90e-01 2.37e-02 3.41e-02
1.56e-03 1.28e-01 1.45e-01 1.19e-02 1.71e-02
7.81e-04 6.42e-02 7.24e-02 5.93e-03 8.54e-03
3.91e-04 3.21e-02 3.62e-02 2.97e-03 4.27e-03
Table 4.3: Maximum Errors via NSFDM for β1 = 0.03, β2 = 0.035
ℓ EX EV EY1 EY2
5.00e-02 4.46e+00 4.71e+00 7.69e-01 1.22e+00
2.50e-02 2.23e+00 2.36e+00 3.88e-01 6.14e-01
1.25e-02 1.11e+00 1.18e+00 1.95e-01 3.09e-01
6.25e-03 5.57e-01 5.89e-01 9.78e-02 1.55e-01
3.13e-03 2.78e-01 2.94e-01 4.89e-02 7.75e-02
1.56e-03 1.39e-01 1.47e-01 2.45e-02 3.88e-02
7.81e-04 6.96e-02 7.36e-02 1.22e-02 1.94e-02
3.91e-04 3.48e-02 3.68e-02 6.12e-03 9.69e-03
Table 4.4: Maximum Errors via RK4 for β1 = 0.03, β2 = 0.035
ℓ EX EV EY1 EY2
5.00e-02 1.96e-01 3.35e-02 3.32e-02 5.90e-02
2.50e-02 9.78e-02 1.67e-02 1.65e-02 2.94e-02
1.25e-02 4.89e-02 8.36e-03 8.26e-03 1.47e-02
6.25e-03 2.44e-02 4.18e-03 4.13e-03 7.34e-03
3.13e-03 1.22e-02 2.09e-03 2.06e-03 3.67e-03
1.56e-03 6.11e-03 1.04e-03 1.03e-03 1.83e-03
7.81e-04 3.06e-03 5.22e-04 5.16e-04 9.17e-04
3.91e-04 1.53e-03 2.61e-04 2.58e-04 4.59e-04
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Table 4.5: Maximum Errors via IFDM for β1 = 0.03, β2 = 0.35
ℓ EX EV EY1 EY2
5.00e-02 1.47e+01 1.68e+01 3.82e-01 5.04e+01
2.50e-02 7.20e+00 8.37e+00 1.92e-01 2.49e+01
1.25e-02 3.56e+00 4.18e+00 9.65e-02 1.24e+01
6.25e-03 1.77e+00 2.08e+00 4.84e-02 6.16e+00
3.13e-03 8.84e-01 1.04e+00 2.42e-02 3.08e+00
1.56e-03 4.41e-01 5.21e-01 1.21e-02 1.54e+00
7.81e-04 2.20e-01 2.60e-01 6.05e-03 7.68e-01
3.91e-04 1.10e-01 1.30e-01 3.03e-03 3.84e-01
Table 4.6: Maximum Errors via NSFDM for β1 = 0.03, β2 = 0.35
ℓ EX EV EY1 EY2
5.00e-02 3.08e+02 1.39e+02 8.23e-01 2.37e+02
2.50e-02 1.57e+02 6.90e+01 4.17e-01 1.22e+02
1.25e-02 7.92e+01 3.43e+01 2.10e-01 6.19e+01
6.25e-03 3.98e+01 1.71e+01 1.06e-01 3.12e+01
3.13e-03 1.99e+01 8.55e+00 5.29e-02 1.56e+01
1.56e-03 9.98e+00 4.27e+00 2.65e-02 7.83e+00
7.81e-04 4.99e+00 2.14e+00 1.32e-02 3.92e+00
3.91e-04 2.50e+00 1.07e+00 6.62e-03 1.96e+00
Table 4.7: Maximum Errors via RK4 for β1 = 0.03, β2 = 0.35
ℓ EX EV EY1 EY2
5.00e-02 1.41e+01 4.71e+00 2.61e-02 8.94e+00
2.50e-02 7.07e+00 2.35e+00 1.30e-02 4.46e+00
1.25e-02 3.53e+00 1.18e+00 6.49e-03 2.23e+00
6.25e-03 1.77e+00 5.87e-01 3.24e-03 1.11e+00
3.13e-03 8.83e-01 2.94e-01 1.62e-03 5.57e-01
1.56e-03 4.41e-01 1.47e-01 8.11e-04 2.78e-01
7.81e-04 2.21e-01 7.34e-02 4.05e-04 1.39e-01
3.91e-04 1.10e-01 3.67e-02 2.03e-04 6.96e-02
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Table 4.8: Maximum Errors via IFDM for β1 = 0.3, β2 = 0.035
ℓ EX EV EY1 EY2
5.00e-02 2.17e+01 2.04e+01 4.30e+01 5.29e-01
2.50e-02 1.08e+01 1.02e+01 2.13e+01 2.67e-01
1.25e-02 5.36e+00 5.07e+00 1.06e+01 1.34e-01
6.25e-03 2.67e+00 2.53e+00 5.29e+00 6.70e-02
3.13e-03 1.34e+00 1.27e+00 2.64e+00 3.35e-02
1.56e-03 6.67e-01 6.33e-01 1.32e+00 1.68e-02
7.81e-04 3.34e-01 3.16e-01 6.59e-01 8.38e-03
3.91e-04 1.67e-01 1.58e-01 3.30e-01 4.19e-03
Table 4.9: Maximum Errors via NSFDM for β1 = 0.3, β2 = 0.035
ℓ EX EV EY1 EY2
5.00e-02 3.71e+02 2.06e+02 2.51e+02 1.24e+00
2.50e-02 1.88e+02 1.02e+02 1.28e+02 6.26e-01
1.25e-02 9.46e+01 5.07e+01 6.49e+01 3.15e-01
6.25e-03 4.74e+01 2.53e+01 3.26e+01 1.58e-01
3.13e-03 2.38e+01 1.26e+01 1.64e+01 7.91e-02
1.56e-03 1.19e+01 6.32e+00 8.19e+00 3.96e-02
7.81e-04 5.95e+00 3.16e+00 4.10e+00 1.98e-02
3.91e-04 2.97e+00 1.58e+00 2.05e+00 9.90e-03
Table 4.10: Maximum Errors via RK4 for β1 = 0.3, β2 = 0.035
ℓ EX EV EY1 EY2
5.00e-02 1.91e+01 8.41e+00 1.10e+01 5.15e-02
2.50e-02 9.54e+00 4.21e+00 5.48e+00 2.57e-02
1.25e-02 4.77e+00 2.11e+00 2.74e+00 1.28e-02
6.25e-03 2.39e+00 1.05e+00 1.37e+00 6.40e-03
3.13e-03 1.19e+00 5.26e-01 6.85e-01 3.20e-03
1.56e-03 5.96e-01 2.63e-01 3.42e-01 1.60e-03
7.81e-04 2.98e-01 1.32e-01 1.71e-01 8.00e-04
3.91e-04 1.49e-01 6.58e-02 8.56e-02 4.00e-04
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Table 4.11: Maximum Errors via IFDM for β1 = 0.3, β2 = 0.35
ℓ EX EV EY1 EY2
5.00e-02 4.29e+00 1.05e+01 6.95e+00 2.94e+01
2.50e-02 2.22e+00 5.25e+00 3.44e+00 1.45e+01
1.25e-02 1.13e+00 2.62e+00 1.71e+00 7.22e+00
6.25e-03 5.69e-01 1.31e+00 8.54e-01 3.60e+00
3.13e-03 2.86e-01 6.53e-01 4.27e-01 1.80e+00
1.56e-03 1.43e-01 3.26e-01 2.13e-01 8.98e-01
7.81e-04 7.16e-02 1.63e-01 1.07e-01 4.49e-01
3.91e-04 3.58e-02 8.16e-02 5.33e-02 2.24e-01
Table 4.12: Maximum Errors via NSFDM for β1 = 0.3, β2 = 0.35
ℓ EX EV EY1 EY2
5.00e-02 2.35e+02 1.01e+02 4.09e+01 1.55e+02
2.50e-02 1.20e+02 5.05e+01 2.10e+01 8.05e+01
1.25e-02 6.06e+01 2.52e+01 1.06e+01 4.10e+01
6.25e-03 3.05e+01 1.26e+01 5.36e+00 2.07e+01
3.13e-03 1.53e+01 6.28e+00 2.69e+00 1.04e+01
1.56e-03 7.65e+00 3.14e+00 1.35e+00 5.21e+00
7.81e-04 3.83e+00 1.57e+00 6.74e-01 2.61e+00
3.91e-04 1.92e+00 7.85e-01 3.37e-01 1.30e+00
Table 4.13: Maximum Errors via RK4 for β1 = 0.3, β2 = 0.35
ℓ EX EV EY1 EY2
5.00e-02 1.15e+01 3.58e+00 1.97e+00 5.34e+00
2.50e-02 5.73e+00 1.79e+00 9.85e-01 2.66e+00
1.25e-02 2.86e+00 8.94e-01 4.92e-01 1.33e+00
6.25e-03 1.43e+00 4.47e-01 2.46e-01 6.65e-01
3.13e-03 7.16e-01 2.23e-01 1.23e-01 3.32e-01
1.56e-03 3.58e-01 1.12e-01 6.14e-02 1.66e-01
7.81e-04 1.79e-01 5.58e-02 3.07e-02 8.30e-02
3.91e-04 8.94e-02 2.79e-02 1.53e-02 4.15e-02
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Table 4.14: Maximum Errors via IFDM for β1 = 0.35, β2 = 0.3
ℓ EX EV EY1 EY2
5.00e-02 3.25e+00 1.26e+01 3.85e+01 1.15e+01
2.50e-02 1.51e+00 6.26e+00 1.89e+01 5.64e+00
1.25e-02 7.26e-01 3.12e+00 9.39e+00 2.79e+00
6.25e-03 3.56e-01 1.55e+00 4.67e+00 1.39e+00
3.13e-03 1.78e-01 7.77e-01 2.33e+00 6.92e-01
1.56e-03 8.92e-02 3.88e-01 1.16e+00 3.46e-01
7.81e-04 4.47e-02 1.94e-01 5.82e-01 1.73e-01
3.91e-04 2.24e-02 9.70e-02 2.91e-01 8.63e-02
Table 4.15: Maximum Errors via NSFDM for β1 = 0.35, β2 = 0.3
ℓ EX EV EY1 EY2
5.00e-02 2.43e+02 1.15e+02 1.50e+02 5.75e+01
2.50e-02 1.24e+02 5.72e+01 7.75e+01 2.94e+01
1.25e-02 6.26e+01 2.85e+01 3.94e+01 1.48e+01
6.25e-03 3.15e+01 1.43e+01 1.99e+01 7.46e+00
3.13e-03 1.58e+01 7.12e+00 9.97e+00 3.74e+00
1.56e-03 7.90e+00 3.56e+00 4.99e+00 1.87e+00
7.81e-04 3.96e+00 1.78e+00 2.50e+00 9.37e-01
3.91e-04 1.98e+00 8.90e-01 1.25e+00 4.69e-01
Table 4.16: Maximum Errors via RK4 for β1 = 0.35, β2 = 0.3
ℓ EX EV EY1 EY2
5.00e-02 1.18e+01 3.88e+00 5.23e+00 2.97e+00
2.50e-02 5.89e+00 1.94e+00 2.61e+00 1.48e+00
1.25e-02 2.94e+00 9.69e-01 1.31e+00 7.39e-01
6.25e-03 1.47e+00 4.84e-01 6.53e-01 3.69e-01
3.13e-03 7.35e-01 2.42e-01 3.27e-01 1.85e-01
1.56e-03 3.68e-01 1.21e-01 1.63e-01 9.22e-02
7.81e-04 1.84e-01 6.05e-02 8.17e-02 4.61e-02
3.91e-04 9.19e-02 3.03e-02 4.08e-02 2.31e-02
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Table 4.17: Order of Convergence of the IFDM for β1 = 0.03, β2 = 0.035
ℓ RX RV RY1 RY2
5.00e-02 1.00 1.00 0.99 0.99
2.50e-02 1.00 1.00 1.00 1.00
1.25e-02 1.00 1.00 1.00 1.00
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
Table 4.18: Order of Convergence of the NSFDM for β1 = 0.03, β2 = 0.035
ℓ RX RV RY1 RY2
5.00e-02 1.00 1.00 0.99 0.99
2.50e-02 1.00 1.00 0.99 0.99
1.25e-02 1.00 1.00 1.00 1.00
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
Table 4.19: Order of Convergence of the RK4 for β1 = 0.03, β2 = 0.035
ℓ RX RV RY1 RY2
5.00e-02 1.00 1.00 1.00 1.00
2.50e-02 1.00 1.00 1.00 1.00
1.25e-02 1.00 1.00 1.00 1.00
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
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Table 4.20: Order of Convergence of the IFDM for β1 = 0.03, β2 = 0.35
ℓ RX RV RY1 RY2
5.00e-02 1.03 1.01 0.99 1.02
2.50e-02 1.01 1.00 1.00 1.01
1.25e-02 1.01 1.00 1.00 1.00
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
Table 4.21: Order of Convergence of the NSFDM for β1 = 0.03, β2 = 0.35
ℓ RX RV RY1 RY2
5.00e-02 0.97 1.01 0.98 0.96
2.50e-02 0.99 1.01 0.99 0.98
1.25e-02 0.99 1.00 0.99 0.99
6.25e-03 1.00 1.00 1.00 0.99
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
Table 4.22: Order of Convergence of the RK4 for β1 = 0.03, β2 = 0.35
ℓ RX RV RY1 RY2
5.00e-02 1.00 1.00 1.00 1.00
2.50e-02 1.00 1.00 1.00 1.00
1.25e-02 1.00 1.00 1.00 1.00
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
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Table 4.23: Order of Convergence of the IFDM for β1 = 0.3, β2 = 0.035
ℓ RX RV RY1 RY2
5.00e-02 1.01 1.01 1.01 0.99
2.50e-02 1.01 1.00 1.01 1.00
1.25e-02 1.00 1.00 1.00 1.00
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
Table 4.24: Order of Convergence of the NSFDM for β1 = 0.3, β2 = 0.035
ℓ RX RV RY1 RY2
5.00e-02 0.98 1.01 0.97 0.98
2.50e-02 0.99 1.01 0.98 0.99
1.25e-02 1.00 1.00 0.99 1.00
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
Table 4.25: Order of Convergence of the RK4 for β1 = 0.3, β2 = 0.035
ℓ RX RV RY1 RY2
5.00e-02 1.00 1.00 1.00 1.00
2.50e-02 1.00 1.00 1.00 1.00
1.25e-02 1.00 1.00 1.00 1.00
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
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Table 4.26: Order of Convergence of the IFDM for β1 = 0.3, β2 = 0.35
ℓ RX RV RY1 RY2
5.00e-02 0.95 1.01 1.01 1.02
2.50e-02 0.98 1.00 1.01 1.01
1.25e-02 0.99 1.00 1.00 1.00
6.25e-03 0.99 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
Table 4.27: Order of Convergence of the NSFDM for β1 = 0.3, β2 = 0.35
ℓ RX RV RY1 RY2
5.00e-02 0.97 1.01 0.96 0.95
2.50e-02 0.98 1.00 0.98 0.97
1.25e-02 0.99 1.00 0.99 0.99
6.25e-03 1.00 1.00 0.99 0.99
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
Table 4.28: Order of Convergence of the RK4 for β1 = 0.3, β2 = 0.35
ℓ RX RV RY1 RY2
5.00e-02 1.00 1.00 1.00 1.00
2.50e-02 1.00 1.00 1.00 1.00
1.25e-02 1.00 1.00 1.00 1.00
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
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Table 4.29: Order of Convergence of the IFDM for β1 = 0.35, β2 = 0.3
ℓ RX RV RY1 RY2
5.00e-02 1.11 1.01 1.02 1.03
2.50e-02 1.06 1.01 1.01 1.02
1.25e-02 1.03 1.00 1.01 1.01
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 0.99 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
Table 4.30: Order of Convergence of the NSFDM for β1 = 0.35, β2 = 0.3
ℓ RX RV RY1 RY2
5.00e-02 0.97 1.00 0.95 0.97
2.50e-02 0.98 1.00 0.98 0.98
1.25e-02 0.99 1.00 0.99 0.99
6.25e-03 1.00 1.00 0.99 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
Table 4.31: Order of Convergence of the RK4 for β1 = 0.35, β2 = 0.3
ℓ RX RV RY1 RY2
5.00e-02 1.00 1.00 1.00 1.00
2.50e-02 1.00 1.00 1.00 1.00
1.25e-02 1.00 1.00 1.00 1.00
6.25e-03 1.00 1.00 1.00 1.00
3.13e-03 1.00 1.00 1.00 1.00
1.56e-03 1.00 1.00 1.00 1.00
7.81e-04 1.00 1.00 1.00 1.00
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Figure 4.1: Profile of Y1(t) generated by IFDM with ℓ = 2
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Figure 4.2: Profile of Y1(t) generated by NSFDM with ℓ = 2
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Figure 4.3: Profile of Y1(t) generated by IFDM with ℓ = 5
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Figure 4.4: Profile of Y1(t) generated by NSFDM with ℓ = 5
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Figure 4.5: Profile of Y2(t) generated by IFDM with ℓ = 2
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Figure 4.6: Profile of Y2(t) generated by NSFDM with ℓ = 2
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Figure 4.7: Profile of Y2(t) generated by IFDM with ℓ = 5
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Figure 4.8: Profile of Y2(t) generated by NSFDM with ℓ = 5
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Figure 4.9: Extended Profile of Y1(t) generated by NSFDM with ℓ = 2
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Figure 4.10: Extended Profile of Y1(t) generated by NSFDM with ℓ = 5
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Figure 4.11: Extended Profile of Y2(t) generated by NSFDM with ℓ = 2
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Figure 4.12: Extended Profile of Y2(t) generated by NSFDM with ℓ = 5
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Our initial aim was to check the performance of the NSFDM as compared to an
IFDM. We did so in a variety of ways. We calculated the errors and looked at the
order of convergence and found that both the approaches have similar results. We
also calculated the reproduction numbers for the various choices of the associated
parameters and found that both of these methods as well as RK4 give the same
answer.
As is seen in the literature that one develops some methods and convinced that
it satisfies a number of properties. However, there are a number of issues through
which one can distinguish between various associated methods. One such method
that we can consider here is the positivity property that we expect the solution to
satisfy. It can be seen from figures 4.1, 4.3, 4.5, 4.7 that the IFDM performs very
poorly in the transient state whereas there is no problem with NSFDM (see, figures
4.2, 4.4, 4.6, 4.8). It preserves the positivity of the solution as needed. In order to
see the extended profile of Y1 and Y2 using NSFDM, we plot some more graphs. See
figures 4.9-4.12.
It is evident from the numerical results that the error is much smaller in the case
of RK4 as compared to other two methods. However, one should note that the order
of the method does not remain four as is expected classically. This unusual but well-
known phenomenon is termed in the literature as “order reduction” (see, e.g., [17, 27])
and is due to the fact being solved over the large intervals, the problem resembles to
the stiff problem.
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Chapter 5
Summary, Conclusions and Future
Plans
In this chapter we summerise our numerical results and discuss main pitfalls. Future
directions will also be indicated in this chapter.
This thesis dealt with design, analysis and implementation of a positivity preserv-
ing numerical method for an HIV model describing the transmission dynamics of two
HIV subtypes in a given community. The area of HIV is introduced with appropriate
details in Chapter 1 where some relevant models and associated literature is also pro-
vided. Then the qualitative analysis for a particular model is carried out in Chapter
2. Some numerical methods are developed in Chapter 3. Extensive numerical simu-
lation are carried out and comparative numerical results were presented in Chapter
4. The methods developed in this thesis can also be extended for some other models
given in Chapter 1.
As is known, the immune system of the body defends the body against bacteria
and viruses. It reduces the basic reproduction number R0 of a disease and may clear
it if R0 becomes less than 1. The AIDS virus attacks the immune system itself,
eventually destroying its ability to reduce R0 below 1 and persists in the body before
this happens by hiding in cells that are not recognized as infected by the immune
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system. Any control policy, in general, aims at reducing R0 below 1. In the case
of the HIV model that we have considered, this R0 is the maximum of the two
reproduction numbers R
(1)
ρ and R
(2)
ρ , which are defined as
R(1)ρ =
β1c(1− ρξ1)
(µ+ γ1 + τ)
and
R(2)ρ =
β2c(1− ρξ2)
(µ+ γ2 + τ)
.
In order to keep these two reproduction numbers less than 1, it is suggested that one
should try to increase the parameters µ and τ and decrease the parameters β1, β2,
and implement various other strategies so that the other parameters ρ, ξ1, ξ2, γ1 and
γ2 increases. This is what exactly the health practitioners should take into account.
Various vaccination strategies could be designed accordingly.
As is pointed out in previous chapter, the model problem that we have solved is
defined over a large interval and that is where stiffness arises. To this end, currently,
we are investigating whether some novel techniques which are well-known for singular
perturbation problems, can be used to resolve such issues.
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Appendix A
On the Reproduction Number R0
The threshold for many epidemiology models is the basic reproduction number R0,
which is defined as the average number of secondary infections produced when one
infected individual is introduced into a host population where everyone is susceptible
[25]. For many deterministic epidemiology models, an infection can get started in
a fully susceptible population if and only if R0 > 1. Thus the basic reproduction
number R0 is often considered as the threshold quantity that determines when an
infection can invade and persist in a new host population.
Note that R0 is also called the basic reproduction ratio [24] or basic reproductive
rate [4].
For the basic endemic models without age structure, the expressions for the basic
reproduction number R0 are intuitively obvious as the product of the contact rate,
the average infectious period, and the fraction surviving the latent period (provided
there is an exposed class in the model). But for more complicated models, expressions
for R0 must be derived from threshold conditions for the stability of the disease-free
equilibrium or the existence of an endemic equilibrium in the feasible region.
The basic reproductive rate, R0, is essentially the average number of successful
offspring that a parasite is intrinsically capable of producing ([1, 2, 25, 26, 55, 56, 82]).
It is, in effect, Fisher’s (1930) ‘net reproductive value’ for the parasite. This concept
is central to any discussion of the overall population biology of an organism. Clearly
a parasitic species must have R0 > 1 if it is to be capable of invading, and establishing
itself within, a host population. For a microparasite (represented by a compartmental
model), R0 is more precisely defined as the average number of secondary infectious
produced when one infected individual is introduced into a host population where
everyone is susceptible. (Note that, a parasite is an organism which obtain food
only by living in or on another organism. Parasites can be categorized into two,
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namely, microparasites and macroparasites. Microparasites may be thought of as
those parasites which have direct reproduction - usually at very high rates within the
host. Macroparasites may be thought of as those having no direct reproduction within
the definitive host. For a macroparasite (represented by a distributional model), R0 is
the average number of female offspring produced throughout the lifetime of a mature
female parasite, which themselves achieve reproductive maturity in the absence of
density-dependent constraints.)
When such a microparasitic infection becomes established in a host population,
the fraction remaining susceptible decreases. Eventually an equilibrium may be at-
tained, with the rate at which susceptible individuals are infected being balanced
against a rate at which newly susceptible individuals appear (usually by birth, but
possibly also by immigration or by loss of immunity). At equilibrium, each infection
will on average produce exactly one secondary infection; that is, at equilibrium the
effective reproductive rate of the parasite is R = 1. If we assume the host population
is homogeneously mixed, in the sense that, on average, all hosts have intrinsically sim-
ilar epidemiological properties ( independent of age, genetic make-up, social habits,
geographical location, etc.), then the number of secondary infections produced by
an infected individual will be linearly proportional to the probability that any one
random contact is with a susceptible individual. In this event, the effective reproduc-
tive rate, R, is equal to the basic rate, R0, discounted by x, the fraction of the host
population that is susceptible: R = R0x. Thus, under the rough approximation of
treating the host population as homogeneously mixed, for a microparasite the equi-
librium condition R = 1 leads to an important relation between R0 and the fraction,
x∗, of the host population that is susceptible at equilibrium:
R0 x
∗ = 1 (1)
Equation (1) has applications which will be discussed later. Beyond this, it has
general interest for ecologists. For one thing, it is notoriously difficult to assess the
intrinsic reproductive capacity, R0, of any species of organism (even humans). It is
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also a problem for ecologists to detemine exactly what density-dependent mechanisms
operate to hold the reproductive rate of natural populations below their intrinsic
capacities - capacities which could, if realized, blanket the world with that species.
Equation (1) resolves both these problems for microparasites: because x∗ can be
found from serological or other data on age-specific susceptibility, the elusive quatity
R0 can be calculated; and the density-dependent process holding R below R0 is simply
the removal of susceptibles by immunity, following infection (which corresponds, in
essence, to a very simple form of predation upon hosts by the parasite). Thus equation
(1) and the surrounding discussion illustrate the concepts of basic reproductive rates
and density-dependent regulation of populations more clearly and quanititatively than
the examples conventionally used in introductory biology textbooks and courses.
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Appendix B
One or more of the following rules [59] can be helpful in designing the non-standard
finite difference methods:
Rule 1. The orders of the discrete derivatives should be equal to the orders of
the corresponding derivatives of the differential equation. (When the orders of the
discrete derivatives are larger than the corresponding orders that appear in the dif-
ferential equation, numerical instabilities in the form of oscillations often appear.
Depending on the particular differential equation, these oscillations may be bounded
or unbounded. The mathematical reason for their occurrence is that the discrete
equations have a larger class of solutions than the differential equation).
Rule 2. Denominator functions for the discrete derivatives must, in general, be
expressed in terms of more complicated functions of the step-sizes than those con-
ventionally used. (These denominator functions, generally, are functions, that are
related to particular solutions or properties of the general solution to the differential
equation).
Rule 3. Nonlinear terms should, in general, be replaced by nonlocal discrete repre-
sentations.
Rule 4. Special conditions that hold for the solutions of the differential equations
should also hold for the solutions of the finite difference scheme.
Rule 5. The scheme should not introduce extraneous or spurious solutions.
Rule 6. For differential equations having N(≥ 3) terms, it is generally useful to
construct finite difference schemes for various sub-equations composed of M terms,
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where M < N , and then combine all the schemes together in an overall consistent
finite difference model.
The first five rules above had originally appeared in [59] and later modified (and/or
interpreted differently but having the similar meanings) as per the individual require-
ments, see, e.g., [5], [53]. For the detailed explanations of these rules, we refer the
readers to [59, 60]. Furthermore, a systematic definition of these nonstandard finite
difference methods is currently being designed in [54].
By the nonstandard finite difference methods, we mean those in which at least one
of the nonstandard modeling rules, proposed by Mickens above, is used.
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Appendix C
Stability Analysis in General
Linear stability of the systems of ordinary differential equations such as arise in in-
teracting population models and reaction kinetics systems (cf. Chapter 3 and 6) is
determined by the roots of a polynomial. The stability analysis we are concerned
with involves linear systems of the vector form
dx
dt
= Ax,
where A is the matrix of the linearised nonlinear interaction/reaction terms: it is the
Jacobian matrix about the steady state—the community matrix in ecological terms.
Solutions are obtained by setting
x = x0e
λt,
in the above equation where x0 is a constant vector and the eigenvalues λ are the
roots of the characteristic polynomial
|A− λI| = 0,
where I is the identity matrix. The solution x = 0 is stable if all the roots λ of
the characteristic polynomial lie in the left-hand complex plane; that is Reλ < 0 for
all roots λ. If this holds then x → 0 exponentially as t → ∞ and hence x = 0 is
stable to small (linear) perturbations. If the system is of nth order, the characteristic
polynomial can be taken in the general form
P (λ) = λn + a1λ
n−1 + ...+ an = 0,
where the coefficient ai, i = 0, 1, ..., n are all real. We tacitly assume an 6= 0 since
otherwise λ = 0 is a solution, and the polynomial is then of order n − 1 with the
equivalent an 6= 0. We require conditions on the ai, i = 0, 1, ..., n such that the zeros
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of P (λ) have Reλ < 0. The necessary and sufficient conditions for this hold are the
Routh-Hurwitz conditions. There are various equilvalent forms of these, one of which
is, together with an > 0,
D1 = a1 > 0,
D2 =
∣∣∣∣∣∣
a1 a3
1 a2
∣∣∣∣∣∣ > 0,
D3 =
∣∣∣∣∣∣∣∣∣
a1 a3 a5
1 a2 a4
0 a1 a3
∣∣∣∣∣∣∣∣∣
> 0,
D4 =
∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣
a1 a3 . . . .
1 a2 a4 . . .
0 a1 a3 . . .
0 1 a2 . . .
. . . . . .
0 0 . . . ak
∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣
> 0, k = 1, 2, ..., n.
These conditions are derived, using complex variable methods, in standard texts on
the theory of dynamical systems [79].
Finally, the following theorem, known as the Lyapunov Stability Theorem, is use-
ful in determining stability of the equilibria.
Theorem. Let x = 0 be an equilibrium point for a system described by
x˙ = f(x)
where f : U → Rn is locally Lipschitz and U ⊂ Rn is a domain that contains the
origin. Let V : U → R be continuously differentiable, positive definite function in U .
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Then,
Case 1. If V˙ (x) =
(
∂V
∂x
)
f is negative semidefinite, then x = 0 is a stable equilib-
rium point,
Case 2. If V˙ (x) is negative definite, then x = 0 is an asymptotically stable equi-
librium point,
where V is called a Lyapunov function. Moreover, if the above conditions holds for
all x ∈ Rn and ‖x‖ → ∞ implies that V (x) → ∞, then x = 0 is globally stable in
Case 1 and globally asymptotically stable in Case 2.
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